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Abbreviations 
 
ALT Alanine aminotransferase Id Inhibitor of differentiation (Inhibitor of DNA binding) 
AST Aspartate aminotransferase IFN Interferon 
Ap Alkaline phosphatase IGF Insulin-like growth factor 
AMP Adenosine-mono-phosphate IgG Immunglobulin G 
BDL Bile duct ligation LAP Latency-associated peptide 
BMP Bone morphogenic protein MAP Mitogen-activated protein 
CBP CREB binding protein MFB Myofibroblast 
CCl4 Carbon tetrachloride MH Mad homology domain 
CMV Cytomegalovirus MMP Matrix metalloproteinase 
CD-1 CD-1 wild type mouse from Charles River Laboratories Myc Myelocytomatosis 
CREB Cyclic AMP response element binding protein NFκB Nuclear factor-kappaB 
DMN Dimethylnitrosamine NASH steatohepatitis  
DTT Dithiotreitol PKC Protein kinase C 
ECM Extracellular matrix SBE Smad binding element 
ECs Endothelial cells siRNA Small interfering RNA 
EMT Epithelial to mesenchymal transition S7∆E1 Smad7 knock out mouse with a deletion in Exon 1 
ERK Extracellular signal-related protein kinase SMA Smooth muscle actin 
FVB Fv-1b allele wild type strain Smurf Smad ubiquitination regulatory factor 1 
FAST1 Forkhead activin signal transducer-1 SnoN Ski-related novel gene 
Fc Antibody fragment c S7tg CRP-Smad7 transgenic mouse with FVB background 
FGF Fibroblast growth factor SV40 Simian Virus 40 
GDF Growth and differentiation factor ATS Anti-thymocyte serum  
HA Hemagglutinin antigen PanIN Pancreatic intraepithelial neoplasia  
HSC Hepatic stellate cell   
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1  Introduction 
Advances in cell and cytokine biology provide insight into molecular mechanisms of tissue fibrosis. Fibrosis in liver, 
kidney, lung, heart, bone marrow, and skin is a major cause of suffering and death and strongly contributes to the costs 
of health care. Fibrosis is not a unique pathologic process but is due to an excess of the same biological events involved 
in normal tissue repair [28]. The release of cytokines in response to injuries is a central event in tissue repair; 
transforming growth factor β (TGF-β) represents a key cytokine that initiates and terminates this process [111].  
1.1 Liver function 
The liver regulates the level of most chemicals in the blood and excretes a fluid product, the bile, which induces fat 
digestion and absorption. All blood leaving the stomach and intestines passes through the liver. The liver processes the 
blood and breaks down nutrients and drugs into forms easier to use for the body. More than 500 vital functions of the 
liver are already identified, including: 
• production of bile to transport waste and to digest fats in the small intestine 
• production of blood plasma proteins 
• production of cholesterol and proteins to transport fats 
• conversion of glucose into glycogen for storage, which is later converted back to glucose for energy production 
• regulation of amino acid blood levels 
• processing hemoglobin (iron storage function) 
• conversion ammonia to urea for excretion 
• clearing the blood from drugs and other poisonous substances  
• regulating blood clotting  
• defending infections by producing immune factors, e.g.,  C-reactive protein (CRP) 
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1.2 Liver fibrosis 
Production of fibrous scar tissue in the liver is a normal response to injuries. In fibrosis this healing process is disturbed. 
Liver fibrosis is defined as the accumulation this fibrous scar tissue in the liver. After hepatocyte damage due to e.g. 
viral infection, heavy alcohol consumption, toxins or trauma, the immune system is activated and the cell repair process 
of the liver is induced. Injury or death (necrosis) of hepatocytes further stimulates inflammatory immune cells to release 
cytokines, growth factors, and chemicals. These messengers activate hepatic stellate cells (HSCs) to produce collagen, 
glycoproteins (such as fibronectin) and proteoglycans. These are deposited in the liver to form the extracellular matrix 
(ECM). At the same time, the process of breaking down or degrading collagen is impaired. In a healthy liver, synthesis 
(fibrogenesis) and degradation (fibrolysis) of matrix tissue are in balance. Fibrosis occurs when scar tissue is generated 
in excess and faster than it is degraded and removed from the liver. 
1.3 Hepatic stellate cells 
Hepatic stellate cells (HSCs) are perivascular mesenchymal cells (in previous literature also named Ito cell, lipocyte, 
perisinusoidal, or fat storing cell) comprising about 15% of the total number of resident liver cells. In normal liver they 
are the principal storage site for retinoids [126]. HSCs constitute a group of cells that are functionally and anatomically 
similar, but different in their expression of cytoskeletal filaments, their retinoid content, and their potential for ECM 
production [57] (Figure 1.1.) 
  
 
Figure 1.1: Sinusoidal events during fibrosing liver injury. 
Changes in the subendothelial space of Disse and sinusoid 
occur as fibrosis develops in response to liver injury. They 
include alterations in both cellular responses and 
extracellular matrix composition. Stellate cell activation 
leads to an accumulation of scar (fibril-forming) matrix. 
This in turn contributes to the loss of hepatocyte microvilli 
and sinusoidal endothelial fenestrae, which results in 
deterioration of the hepatic function. Kupffer cell 
(macrophage) activation accompanies liver injury and 
contributes to paracrine activation of stellate cells [40].  
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HSCs have an intriguing embryologic origin. Recent evidence suggests that they are neural crest-derived because they 
express glial fibrillary acidic protein and nestin [85]. A neural crest origin is further supported by studies with rat neural 
crest stem cells, which differentiate into myofibroblasts expressing α-smooth muscle actin (αSMA) [77]. αSMA in turn 
is a marker of activated HSCs. 
1.4 Hepatic stellate cell activation 
Following liver injury of any etiology, HSCs undergo a response known as "activation", which is the transition of 
quiescent cells into proliferative, fibrogenic, and contractile myofibroblasts.  
HSC activation is a remarkably pleiotropic yet tightly programmed response occurring in a reproducible sequence 
(Figure 1.2). The organization of HSC activation into a defined temporal sequence provides a framework, in which 
cellular events can be placed into a discrete biological context. Early events have been termed initiation (also referred to 
as the "preinflammatory" stage). Initiation encompasses rapid changes in gene expression and phenotype that render the 
cells responsive to cytokines and other local stimuli. Initiation is associated with transcriptional events and induction of 
immediate early genes. It results from paracrine stimulation due to rapid, disruptive effects of liver injury on the 
homeostasis of neighboring cells and from early changes in ECM composition. Perpetuation incorporates those cellular 
events that amplify the activated phenotype through enhanced cytokine expression and responsiveness; this component 
of activation results from autocrine and paracrine stimulation, as well as from accelerated ECM remodeling.  
 
 
Figure 1.2: Phenotypic features of hepatic stellate cell activation 
during liver injury and resolution. Following liver injury, HSCs 
undergo "activation," which characterizes a transition from 
quiescent vitamin A-rich cells into proliferative, fibrogenic, and 
contractile myofibroblasts. The major activation dependent 
phenotypic changes include proliferation, contractility, 
fibrogenesis, matrix degradation, chemotaxis, retinoid loss, and 
white blood cell chemoattraction. Key mediators underlying these 
effects are shown. The fate of activated HSCs during resolution of 
liver injury is uncertain but may include reversion to a quiescent 
phenotype and/or selective clearance by apoptosis [40].  
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Changes in matrix protease activity lead to a remodeling of the hepatic ECM during liver injury, which both directly and 
indirectly accelerates HSC activation. HSCs express virtually all key components required for matrix degradation 
[6],[38]. In particular, they are a source of matrix metalloproteinase (MMP)-2 as well as stromelysin/MMP-3 [6], each 
of which degrades the normal subendothelial ECM. This degradation accelerates its replacement by fibril-forming 
collagen, which further activates stellate cell growth and MMP-2 production in a positive feedback loop [115],[8]. 
Through the up-regulation of tissue metalloproteinase (TIMP)-1 and -2, activated HSCs can also inhibit the activity of 
interstitial inhibitors like collagenases, which additionally favors the accumulation of scar [6]. 
1.5 TGF-β in tissue repair 
Healing of a wound is composed of a coordinated sequence of biological events beginning with hemostasis induced by 
platelets. This is followed by an invasion of inflammatory cells and fibroblasts to the crisis area for de novo formation of 
new ECM and blood vessels and to induce proliferation of cells for restoring the tissues [28].  
TGF-β1 plays an important role in each of these aforementioned events, which can be reproduced by its administration 
to normal tissue [97], [98]. Platelets contain high concentrations of TGF-β1 and platelet-derived growth factor (PDGF), 
which are released into the tissue at the site of injury. As a result of injury, inactive (latent) TGF-β1, deposited locally to 
the extracellular matrix (ECM), is activated. In femtomolar concentrations, TGF-β1 is strongly chemotactic for 
neutrophils, T-cells, monocytes, and fibroblasts [124], [93], [98]. Moving to the site of injury, these cells become 
activated by higher (picomolar) concentrations of TGF-β1. Monocytes begin to secret fibroblast growth factor (FGF), 
tumor necrosis factor (TNF), and interleukin-1 (IL-1), and fibroblasts increase the synthesis of ECM proteins [98]. 
TGF-β1 stimulates infiltrating cells and resident cells to produce more of it self. This autoinduction intensifies the 
biological effects of TGF-β1 at the site of injury and has a central role in chronic disease [55]. At normal concentrations, 
TGF-β1 regulates FGF (in endothelial cells), PDGF (in smooth-muscle cells and fibroblasts), TNF and IL-1 (in 
monocytes) by stimulating or inhibiting their production or modulating their actions to synchronize and control the repair 
process [7], [89]. Neonatal mice, in which the TGF-β1 gene was knocked out, live for several weeks until the maternal 
supply of TGF-β1 is gone, and then die of a systemic autoimmune-like disease with markedly elevated tissue 
concentrations of TNF and IL-1 [62],[108]. TGF-β1 also inhibits T-cell and B-cell function and their production of TNF-
α and IL-1 [15]. TGF-β1 further modulates cytotoxicity of macrophages by suppressing superoxide and nitric oxide 
production [99; 123].  
TGF-β1 can function as an agonist or antagonist of cell proliferation and inflammation and it consistently induces 
deposition of ECM [99]. Accumulation of matrix is the chief  pathologic feature of fibrotic diseases [102]. Figure 1.3 
illustrates how TGF-β1 causes the deposition of ECM by simultaneously stimulating cells to increase the synthesis of 
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matrix proteins several fold, decrease production of matrix-degrading proteases, increase inhibitors of these proteases, 
and modulate the expression of integrins for enhanced cellular adhesion to the matrix. These comprehensive effects on 
the ECM reflect the diverse biological properties of TGF-β and are part of a negative-feedback loop regulating the 
expression of TGF-β [102]. TGF-β binds to proteoglycans in the matrix or near the cell surface, and such binding may 
act as a signal to terminate TGF-β production after tissue repair is complete. 
The regulation of TGF-β secretion and action involves complex post-transcriptional events, including among others 
messenger RNA (mRNA) stabilization, assembly and activation of the latent TGF-β complex, as well as the modulation 
of receptor expression [56].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Actions of TGF-β in the healing process of injured tissue. Platelets release TGF-β at the site of tissue injury. To repair the damage, 
TGF-β induces the deposition of ECM by simultaneously stimulating the production of new matrix proteins (fibronectin, collagens, and 
proteoglycans), blocking matrix degradation by decreasing the synthesis of proteases and increasing the production of protease inhibitors, and by 
modulating the expression of cell-surface integrins in a manner that enhances cell-matrix interaction and matrix assembly. TGF-β also induces 
its own production, thus amplifying the biological effects [11].  
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1.6 TGF-β in fibrogenesis 
The fibrogenic potential of TGF-β was established with repeated injections of higher doses into rats during two weeks, 
which resulted in serious systemic effects, including marked fibrosis in kidneys, liver and at the injection site [114]. 
Severe cachexia and generalized tissue fibrosis developed in mice given TGF-β intraperitoneally for 10 days [147]. A 
clinical counterpart of these results might be the rapid onset of liver and lung fibrosis in patients with advanced breast 
cancer, who receive high-dose chemotherapy in preparation for autologous bone marrow transplantation. The plasma 
TGF-β concentration, if measured after induction of the chemotherapy, strongly correlates with the development of 
pulmonary fibrosis or hepatic veno-occlusive disease after high-dose chemotherapy and autologous bone marrow 
transplantation [3]. The source of the elevated plasma TGF-β concentrations in these patients is unknown. 
It is unknown how TGF-β production is normally terminated. It is suggested that repeated injury with continued 
autoinduction of TGF-β overrides the normal termination signals, thus creating a chronic vicious circle of TGF-β 
overproduction, as shown in figure 1.4 [10]. 
 
Figure 1.4: Overproduction of TGF-β in 
fibrogenesis. In normal tissue repair, 
production of TGF-β and ECM is 
terminated by unknown mechanisms as the 
damaged tissue heals. In patients with 
chronic diseases, repeated tissue injury, a 
defect in TGF-β regulation, or both lead to 
the continuous production of TGF-β and 
ECM, finally resulting in tissue fibrosis 
[10].  
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1.7 TGF-β/Smad signal transduction 
TGF-β superfamily members bind to serine/threonine kinase receptors. TGF-β receptors comprise two structurally 
similar subfamilies, the type I and type II receptors, both with small cysteine rich extracellular regions and intracellular 
portions consisting mainly of their kinase domains. Type I receptors have a region rich in glycine and serine residues 
(GS domain) in vicinity to the receptor kinase domain [50]. To transmit a signal, type II and type I receptors act in 
sequence [132]. TGF-β first binds to TβRII, which resides in the cell membrane in an oligomeric form with intrinsic 
kinase activity; TβRI is then recruited and phosphorylated in its GS domain by TβRII, leading to activation of its kinase 
activity and subsequent intracellular signaling [70; 91]. Betaglycan, a transmembrane proteoglycan also known as TGF-
β type III receptor (TβRIII) [66], presents TGF-β to the other receptors and allows high-affinity binding of TGF-β to 
TβRII. But betaglycan does not transduce a signal by itself [100], [19].  
Smad proteins 
Following ligand activation, signaling from TβRI to the nucleus occurs predominantly by phosphorylation of 
cytoplasmic mediators belonging to the Smad family [91], [71], [72]. Type I receptors specifically recognize and 
phosphorylate ligand-specific receptor-activated Smads (R-Smads, Fig. 1. 5). 
Figure 1.5: Structural domains of R-Smads. R-
Smads consist of two conserved globular 
domains known as MH (Mad homology) 1 and 
MH2 domains, connected by a linker region. In 
the basal state, R-Smads remain in an inactive 
conformation through an auto-inhibitory 
MH1/MH2 interaction. Phosphorylation of the 
C-terminal SSXS motif by activated TβRI results 
in R-Smad activation. Heteromerization with 
Smad4, and subsequent translocation into the 
cell nucleus follow. The MH1 domain of Smad3 
recognizes the DNA sequence CAGAC; the 
MH2 domain is involved in protein/protein 
interactions with Co-Smad4, transcriptional 
coactivators and corepressors [122]. 
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R-Smads are recruited to the activated TβRI by a membrane bound cytoplasmic protein called Smad anchor for receptor 
activation (SARA) [119]. R-Smads include Smad1, Smad5 and Smad8 downstream of the bone morphogenetic protein 
(BMP) cascade, and Smad2 and Smad3 downstream of TGF-β and activin signaling. R-Smads consist of two conserved 
Mad-homology (MH) domains that form globular structures separated by a linker region [106]. The N-terminal MH1 
domain has DNA-binding activity, whereas the C-terminal MH2 domain has protein-binding properties. 
Phosphorylation of R-Smads by type I receptors occurs on two serine residues within a conserved SS(M/V)S-motif at 
the C-terminus of the Smads [72], [71]. Upon phosphorylation by TβRI, R-Smads form heteromeric complexes with a 
Co-Smad, Smad4. Smad4 is the product of the tumor suppressor gene “deleted in pancreatic carcinoma-4” (DPC-4) [44]. 
The Smad4 MH1 domain can directly interact with DNA [143] and binds to the phosphorylated C-terminus of activated 
R-Smads [47]. The MH2 domain is important for transcriptional activation [29], [144] and for direct protein interactions 
with the MH1 domain of R-Smads  [107]. Smad4 lacks the COOH-terminal SSV/MS motif found in R-Smads and 
neither binds nor is phosphorylated by activated type I receptors [67], [81]. R-Smad/Smad4 complexes are then 
translocated into the nucleus by a mechanism involving the cytoplasmic protein importin [133], [63] and function as 
transcription factors, binding DNA either directly or in association with other DNA binding proteins [91], [71], [72]. A 
third group of Smad proteins, the inhibitory Smads (I-Smads), Smad6 and Smad7, prevent R-Smad phosphorylation and 
nuclear translocation of R-Smad/Smad4 heterocomplexes [51], [81]. Following target gene transcription, Smad 
complexes are released from the chromatin and undergo ubiquitination, followed by proteasomal degradation [146]. A 
summary of the various steps of TGF-β signaling through the Smad cascade is provided in Figure 1. 6. 
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Figure 1.6: Schematic representation of the Smad signaling cascade downstream of the TGF-β receptors. Initiation of signaling occurs when 
TGF-β binds to the serine/threonine kinase known as TβRII. Ligand-bound TβRII interacts with and phosphorylates the transducer receptor, 
TβRI. Activated TβRI then recruits and phosphorylates R-Smads, which associate to Co-Smad4. The heterocomplex translocates into the 
nucleus where it acts as a transcriptional regulator of target genes [16]. Smad7 blocks the TGF-ß signal cascade on the level of R-Smad 
phosphorylation.  
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1.8 Animal models for liver disease 
Several animal models for liver fibrosis have been established in the past and are still in use. They have contributed to 
the understanding how the disease develops and progresses.  
Weng et al., 2001 [128] induced hepatic fibrosis successfully by subcutaneous injection of carbon tetrachloride (CCl4) 
into 150 and intraperitoneal injection of dimethylnitrosamine (DMN) into 196 rats to evaluate the antifibrotic effect of 
recombinant human Gamma-Interferon (IFN-γ) and to observe its effect on moderate chronic hepatitis B virus fibrosis. 
They concluded that IFN-γ is effective in treating rat liver fibrosis induced by either CCl4 or DMN. The higher the dose, 
the better the effect. IFN-γ is also effective for patients with moderate chronic hepatitis B viral fibrosis. 
The antifibrotic effect of Smad7 was demonstrated by Dooley et al., 2003 [34] who subjected Sprague Dawley rats to 
bile duct ligature (BDL) causing cholestasis, periductular inflammation, and fibrosis. Rats were injected with AdSmad7, 
AdLacZ, or saline, either via the portal vein at the time of surgery or via the tail vein 1 and 2 weeks later.  
1.8.1 Induction of liver damage with dimethylnitrosamine 
Dimethylnitrosamine (DMN) is a hepatotoxin, mutagen and carcinogen, which is produced from the reaction of its 
precursors dimethylamine (DMA) or trimethylamine (TMA) and nitric acid or oxides of nitrogen in the vapor phase 
[69], [92]. Its hepatotoxicity was first reported by Barnes and Magee (1954) following an industrial accident. Toxicity 
produced by DMN is mediated by its reactive metabolites. DMN primarily targets the liver, which contains necessary 
enzymes for its metabolic activation, e.g., microsomal membrane-bound cytochrome P-450 II E1 (Cyp2E1) [135], [136], 
[141]. Activation and degradation of DMN produces formaldehyde, methanol and alkylating intermediates, which react 
with nucleic acids and proteins to form methylated macromolecules. In rats, DMN causes severe necrosis and deposition 
of ECM proteins, particularly of collagen in the liver [2], [105]. Lethal dose 50 (LD50) in rat for DMN is 26 mg/kg or 
78 ppm over 4 hours [24]. A single dose of about 25 mg/kg DMN administered orally or by intravenous, intraperitoneal 
or subcutaneous injection produces serious destruction of liver tissue accompanied by hemorrhages into liver and lungs. 
Treatment is frequently accompanied by serious accumulation of fluid in the abdominal area and blood deposition in the 
lumen of the intestine. Death usually occurs within 2-4 days or the animal recovers completely. Rabbits, mice, guinea 
pigs, and dogs develop similar liver damage with this treatment [68].  
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1.8.2 Induction of liver fibrosis with carbon tetrachloride 
Carbon tetrachloride (CCl4) causes liver injury by damaging microsomes from the endoplasmic reticulum and ribosomes 
through free radical induced lipid peroxidation and direct free radical attack. Most of the adverse effect is provided by 
CCl3● radical production via the cytochrome P-450 system [95]. More recently, it was reported that CCl3● rapidly reacts 
with O2 and forms CCl3-O2● [87]. Today CCl4 proves highly useful in experiments studying hepatotoxic effects [109]. It 
consistently induces liver injury in many species, including non-human primates, [142] and man. Investigation of the 
effects of CCl4 on metabolic processes in the liver have been performed using living animals [54] as well as perfused 
livers [73] and cultured hepatocytes [46]. In the presented study, mice routinely obtained intraperitoneal injections of 
CCl4 (25 % vol/vol in mineral oil, 50 µl/25 g body weight) two days a week for a period of 8 weeks. 
1.8.3 Establishing liver damage with bile duct ligation 
Venous blood from the ileum is distributed from the portal vein through the sinusoids throughout the liver. Hepatocytes 
extract bile acids from sinusoidal blood and only little escapes from healthy livers into the systemic circulation. Bile 
acids are then transported across the hepatocytes and secreted into canaliculi from where they are transported to the 
gallbladder. Based on this mechanism, bile duct ligation (BDL) was established as a further method to induce liver 
damage. It is achieved by a surgical procedure, tying a ligature tightly around the bile duct in order to interrupt the 
enterohepatic recirculation of bile to the gallbladder. This model for in vivo studies generates liver fibrogenesis very 
efficiently based on cholestasis [60].  
1.9 Blunting fibrogenesis by blocking TGF-β 
The role of TGF-β as a potent profibrotic cytokine has been demonstrated in a number of animal models [12], [59]. 
Overexpression of TGF-β in transgenic mice results in liver and kidney fibrosis [103]. Several lines of evidence indicate 
that fibrosis is caused by unbalanced expression of TGF-β in several organs e.g., liver, kidney and heart. For that reason 
a sensible antifibrotic therapy must be based on controlling of TGF-β expression. 
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1.9.1 Anti-TGF-β antibodies 
TGF-β is usually secreted in a biologically inactive form as small (SLTC) or large latent complex (LLTC). The inactive 
ECM-bound LLTC, containing mature TGF-β, latency-associated peptide (LAP) and latent TGF-β binding protein-1 
(LTBP-1) is released from the ECM by proteases, and activated at the cell surface to release mature TGF-β [41].  
Several lines of evidence indicate that TGF-β beside being involved in liver fibrosis plays a role in the pathogenesis of 
renal disease associated with diabetes and hypertension [10], [61]. Circulating and local concentrations of TGF-β in the 
kidney are elevated in humans and experimental animals with glomerulonephritis, diabetic nephropathy, and 
hypertensive glomerular injury [10]. Moreover, transgenic animals overexpressing TGF-β, develop glomerular lesions 
and tubulointerstitial renal disease that resemble the types of lesions seen in patients with diabetes or hypertension [13]. 
It was reported, that anti-latent TGF-β binding protein-1 (anti-LTBP-1) antibodies were used to prevent progression of 
glomerulosclerosis [49] based on blunting LTBP-ECM interactions. 
Further, a murine monoclonal antibody (1D11) that neutralizes all three isoforms of TGF-β (β1, β2, and β3) successfully 
abrogated the development of hypertension, glomerulosclerosis, and/or tubulointerstitial renal disease in Dahl salt-
sensitive (Dahl S) rats fed a high-salt diet for 3 weeks. This indicates that chronic treatment of Dahl S rats with anti-
TGF-β antibodies significantly reduces blood pressure, proteinuria and albuminuria. 
1.9.2 Dominant-negative and soluble TGF-β type II receptors  
A promising strategy to prevent fibrosis is eliminating TGF-β signaling by adenovirus-mediated local expression of a 
dominant-negative TβRII in the liver of rats treated with DMN [94]. Since transphosphorylation of the type I receptor by 
the type II receptor is essential for TGF-β signal propagation [132], a mutated type II receptor, e.g., truncation of its 
kinase domain [131] or substituted with one critical amino acid resulting in loss of transphosphorylation activity [21] 
can inhibit many signaling responses induced by TGF-β. Accordingly, rats receiving a single application of adenoviral 
vectors expressing a truncated (kinase domain) human TβRII (AdCATβ-TR) via the portal vein, displayed significantly 
attenuated liver fibrosis as assessed by histology and hydroxyproline content. All AdCATβ-TR treated rats remained 
alive, and their serum levels of hyaluronic acid and transaminases remained at low levels, whereas control animals died 
due to liver dysfunction [94]. Functionality of this construct was further confirmed in mink lung epithelial cells 
(Mv1Lu), where TGF-β-induced antiproliferative signaling was blocked by AdCATβ-TR [134]. Further, a soluble TβR-
II protein was successfully used to ameliorate liver fibrosis based on scavenging exogenous TGF-β [145], [120]. The 
soluble receptor fusion protein acts by binding TGF-β1 (as well as TGF-β3) with high affinity, thereby preventing the 
Chapter 1 Introduction 20 
 
interaction of TGF-β1 with its cell surface receptors and effectively neutralizing TGF-β1 bioactivity. Two different 
soluble TGF-β II receptor constructs were composed either of the extracellular portion of mouse TβR-II and the Fc 
(fragment crystallizable) portion of mouse immunoglobulin (Ig) G [145], or of an entire ectodomain of human TβRII 
fused to the Fc portion of human IgG expressed by AdTbeta-ExR. [120]. Chimeric TβR-II:Fc proteins localize 
predominantly to sites of TGF-β1 activity and attenuated markedly liver fibrosis in rats exposed to DMN [120], reduced 
postangioplasty vascular intimal lesion formation in rats [110], bleomycin-induced lung fibrosis in hamsters [126], and 
hepatic fibrosis after bile duct ligation in rats [43]. 
Recently a similar strategy was used to block the actions of tumor necrosis factor (TNF) α in rheumatoid arthritis. The 
approach was already tested successfully in a randomized clinical trial [127], thus showing applicability, safety, and 
clinical potential of soluble cytokine receptors. 
1.9.3 Smad7 
To interfere with the TGF-β signaling pathway further downstream may lead to a more specific blunting, since not all 
TGF-β effects would be abrogated. Nakao and his coworkers were the first to use adenoviral overexpression of 
antagonistic Smad7 to inhibit TGF-β effects in a fibroproliferative disease [83]. Delivery of CMV-Smad7 adenovirus via 
intratracheal injection to C57BL/6 mice 8-12 hours after initiation of bleomycin-induced lung fibrosis led to inhibition 
of profibrogenic TGF-β signaling and subsequent responses in animal lungs. Overexpression of the BMP specific 
inhibitor Smad6 was also used in these studies but displayed no beneficial effect. 
Accordingly, we used this approach and showed that Smad7 is equally effective in inhibiting liver fibrosis [34]. Ligation 
of the common bile duct (BDL) was used to induce liver fibrosis in rats. Subsequently the animals received injections of 
an adenovirus carrying Smad7 cDNA into the portal vein during surgery and via the tail vein at later stages. Smad7 
overexpressing BDL rats displayed reduced collagen expression and hydroxyproline content in total liver lysates. In 
addition, α-smooth muscle actin (α-SMA) staining was strongly reduced in animals treated with the Smad7 expression 
cassette compared to a LacZ control, indicating a significant reduction of activated HSCs in vivo. Importantly, such a 
beneficial effect was also observed when Smad7 was expressed in animals with established fibrosis. Additionally, the 
effect of Smad7 on TGF-β signaling and activation of HSCs was analysed in primary cultured cells. Ectopic Smad7 
expression arrested transdifferentiation and blocked TGF-β signal transduction, shown by inhibition of Smad2/3 
phosphorylation, nuclear translocation of activated Smad complexes, and activation of (CAGA)9-MLP-Luc. This 
resulted in decreased collagen I expression and destruction of the fibrillar organization of the α-SMA cytoskeleton. Our 
data suggest that gene transfer of Smad7 inhibits experimental liver fibrogenesis in vivo. The underlying mechanism 
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most likely involves inhibition of TGF-β signaling and HSC transdifferentiation. However, while interpreting the data 
and creating a mechanistic model, it has to be taken into account that Smad7 is also very efficient in abrogating the 
effects of other members of the TGF-β family, e.g., isotypes 2 and 3 and BMPs. In addition, Smad7 may also have other, 
yet unidentified functions, also contributing to the observed effects. Thus, its involvement in apoptosis was described 
recently [35] and its clearly documented localization within the nucleus can still not be related to any function of Smad7. 
Therefore, further research about details of TGF-β signaling and the impact of Smad7 in the different cell types of the 
liver is needed to optimize treatment strategies based on Smad7. 
Smad7 was also used as antifibrotic tool in several models of kidney fibrosis. Lan and coworkers [65] transferred a 
doxycycline-regulated Smad7 gene into rat kidneys. Induction of Smad7 resulted in complete inhibition of Smad2/3 
nuclear translocation and tubulointerstitial fibrosis, as evidenced by decreased expression of α-SMA and collagen types 
I and III. Similarly, decreased fibrosis could be detected if Smad7 was introduced one day after ureter ligation by 
injection [113]. 
Another possibility to block certain pathways more specifically will be to inhibit downstream targets of TGF-β, directly. 
Smad3, which was identified as important regulator of fibrotic responses in many different organs might be such a target 
[39]. 
1.9.4 Compound drugs to inhibit profibrogenic TGF-β signaling 
Another strategy of TGF-β neutralization is targeting the activation process of latent TGF-β. Thus, the serine protease 
inhibitor camostat mesilate was used to attenuate hepatic fibrogenesis at least in part by inhibiting plasmin activity [86]. 
Plasmin treatment of cultured HSCs induces release of TGF-β from the matrix resulting in an increased TGF-β 
dependent gene response, e.g. upregulation of Smad7 mRNA expression [17]. This indicates that plasmin participates in 
the activation process of latent TGF-β. Interestingly, camostat mesilate also blunted the effect of recombinant, active 
TGF-β itself, suggesting an additional antagonizing mechanism of this drug or plasmin. This was confirmed by the 
observation that the phenotype of plasmin knock out animals is different from that of TGF-β1 knock-out mice [22], 
[108].  
Thrombospondin-1 (TSP-1), an ECM protein involved in the regulation of cellular responses following injuries ([96] 
plays an important role as an activator of the small latent TGF-β complex [26], [79]. TSP-1 expression is increased in 
livers from patients who suffer from congenital hepatic fibrosis [36]. A peptide derived from the latency-associated 
peptide (LAP), i.e. Leu-Ser-Lys-Leu (LSKL), inhibits the activation of TGF-β1 by blunting the LAP-TSP-1 interaction, 
which is necessary for the TSP-1 mediated activation mechanism [58]. To study the effects of LSKL on hepatocyte 
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damage and fibrogenesis in DMN-induced liver fibrosis, rats obtained an intraperitoneal injection of DMN or saline 
three times per week for four weeks. In addition, the animals were treated with LSKL, a control peptide, or saline daily. 
LSKL peptides prevented progression of hepatic damage and fibrosis through inhibition of TGF-β1 activation and 
subsequent signal transduction in vivo. At the cellular level, neutralization of TSP-1 in activated HSCs abrogated TGF-β 
signaling as demonstrated with an adenoviral reporter construct, (CAGA)9-MLP-Luc, containing a Smad3/Smad4 
response element driving expression of luciferase [18], [32]. While these data strengthen the potential importance of 
TSP-1 in TGF-β mediated hepatic fibrosis in vivo, the mechanism leading to activation of latent TGF-β1 and subsequent 
initiation of intracellular signaling in liver cells needs further examination.  
A promising method to disrupt the TGF-β/Smad pathway is to block the serine/threonine kinase activity of TβRI, also 
known as activin receptor-like kinase (ALK) 5. The identification of GW6604 (2-phenyl-4-(3-pyridin-2-yl-1H-pyrazol-
4-yl) pyridine), an ALK5 inhibitor, allowed de Gouville et al. [30] to evaluate the therapeutic potential of inhibiting the 
TGF-β pathway in different models of liver disease. The ALK5 inhibitor was tested in TGF-β overexpressing transgenic 
mice exhibiting liver hepatectomy, in an acute model of liver disease and in a chronic model of dimethylnitrosamine 
(DMN)-induced liver fibrosis. In vitro GW6604 inhibited autophosphorylation of ALK5 and in a cellular assay it 
inhibited TGF-β-induced transcription of PAI-1. In vivo GW6604 increased liver regeneration in TGF-β overexpressing 
mice, which had undergone partial hepatectomy. In an acute model of liver disease, GW6604 reduced the expression of 
collagen Iα1 by 80%. In a chronic model of DMN-induced fibrosis, mortality was prevented and DMN induced 
elevations of mRNA encoding collagen Iα1, Iα2, III, TIMP-1 and TGF-β were reduced by 50–75 % by the 
administration of GW6604. Inhibition of matrix genes overexpression was accompanied by reduced matrix deposition 
and reduction in liver function deterioration. 
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1.10 C-reactive protein in liver damage 
C-reactive protein (CRP) is a phylogenetically highly conserved plasma protein with homologs in vertebrates and 
invertebrates that participates in the systemic response to inflammation. Its plasma concentration increases during 
inflammatory stages, which is useful for clinical purposes. CRP is a pattern recognition molecule, which binds to 
specific molecular configurations typically exposed during cell death or found on the surfaces of pathogens like 
lipopolysacharide (LPS). Its rapid increase in synthesis within hours after tissue injury or infection suggests that it 
contributes to host defense and is part of the innate immune response. 
CRP is a β-globulin and as a hallmark for inflammation it is primarily synthesized in hepatocytes [78]. Preliminary 
evidence suggests that CRP is also expressed in vascular cells and atherosclerotic lesions [138], [20]. An inducer of CRP 
synthesis is Interleukin-6 (IL-6), produced and secreted from macrophages activated as a reaction to pathogenic agents 
like LPS and bacterial infection. The IL-6 effect can be enhanced by interleukin-1β (IL-Iβ) [64]. CRP is a component of 
the acute phase protein and the congenital immune system in humans. It imitates an antibody by binding 
phosphorylcholine on the bacterial cell membrane in the presence of Ca++ and triggers the complement cascade. CRP is 
taken into the cells by Toll-like receptors (TLR). This allows an immediate response to microbial invasions before the 
development of active immunity. TLRs are conserved throughout evolution, are the primary sensors of this innate 
(natural) immunity and thus play a crucial role in the primary defense against infections [112]. Inflammatory effects of 
CRP as responses to chronic bacterial infections lead to serious organ damage by triggering a primary defense 
mechanism including migration of immune cells to the crisis regions.  
Even though serum amyloid proteins rather than CRP are the major acute phase proteins in mice [90] and [130], the 
expression of the human CRP gene is regulated in transgenic mice as it is regulated in humans [25]. Thus the human 
CRP promoter offers a useful tool to express transgenically derived proteins under tight induction control specifically in 
hepatocytes of mice. 
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Structure of C-reactive protein 
 
 
 
Figure 1.7: Crystal structure of C-reactive protein complexed with phosphocholine [116]   ViewerPro 4.2 software (Accelrys, San Diego, CA) 
was used to generate the ribbon diagram of the x-ray crystal structure of CRP-phosphocholine complex obtained from Brookhaven Protein Data 
Bank (PDB entry 1B09 [PDB] ). Calcium ions in yellow, phosphocholine in green. 
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1.11 Aim of the study 
The study presented here is based on previous work [34], where we succeeded in ameliorating fibrogenesis in BDL rats 
by injection of AdSmad7 via the portal/tail vein. Smad7 overexpression in rats with BDL displayed reduced collagen 
and α-SMA expression as well as decresed hydroxyproline content in the liver compared to animals treated with 
AdLacZ. A beneficial effect was even observed when Smad7 was expressed in animals with established fibrosis. In this 
model Smad7 was expressed in all liver cell types. In the present study, we were interested to investigate the effects of 
Smad7 overexpression specifically in hepatocytes. Therefore CRP-Smad7 transgenic mice expressing Smad7 under the 
control of the hepatocyte specific CRP promoter were generated for this purpose. Ectopic Samd7 expression can be 
induced by LPS. As reference strains FVB and CD-1 wild type as well as mice with a disrupted Smad7 gene (S7∆E1) 
were examined. Animals were treated with CCl4 to induce fibrosis and with LPS to stimulate transgenic Smad7 
overexpression. After 8 weeks, tissues were analysed for the expression of fibrotic marker proteins. Sirius red staining 
was performed to assay collagen deposition and immunostaining was used to quantify the expression of α-SMA. 
Further, Western blot analysis of whole liver protein lysates was done and liver enzyme activities in the serum were 
measured. 
The results show that Smad7 overexpression in hepatocytes attenuates production of fibrotic marker proteins, e.g., α-
SMA, collagen, hyaluronic acid, hydroxyproline and serum enzymes by up to 70% compared to controls.  
In summary, this investigation indicates that Smad7 can inhibit or at least attenuate the development of liver fibrosis by 
reducing TGF-β signaling in hepatocytes. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 General chemicals 
Table 2.1: General chemicals  
 
Reagent Company Cat. No. 
Agarose DNA Qbiogene,Heidelberg,Germany  AGAH0250 
Agarose / DNA Biozym, Hess. Oldendorf, Germany 97342 
Citric acid, monohydrate Calbiochem, Darmstadt, Germany 231211 
Diaminobenzidine Sigma, Munich, Germany D-5905 
Dithiothreitol (DTT) Sigma, Munich, Germany D-9779 
Sodium chloride Sigma, Munich, Germany S-9625 
NaOH, 2 mol/l Merck, Darmstadt, Germany 1.091361.000 
Tris (hydroxymethyl) aminomethane Merck, Darmstadt, Germany 1.08382.1000 
Tween 20 Merck, Darmstadt, Germany 8.22184.0500 
Titriplex III Merck, Darmstadt, Germany 1.08418.0250 
Picric acid solution drugstore of medical clinical Aachen, Germany   
Phosphate buffered saline, pH 7,4 (10 x) Gibco, Karlsruhe, Germany 70011-036 
Potassium chloride Merck, Darmstadt, Germany 1.04936.0500 
TAE Buffer 50 x pH 8.3 Promega, Mannheim, Germany H5231 
Ethidiumbromide solution 
10 mg/ml 
BIO-RAD,Hemel Hempstead, UK 161-0433 
Gene RulerTM 100 bp DNA Ladder Plus Fermentas, St. Leon-Rot, Germany SM0321 
Gene rulerTM 1Kb DNA ladder Plus Fermentas, St. Leon-Rot, Germany SM0311 
Loading dye solution x 6 Fermentas, St. Leon-Rot, Germany R0611 
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2.1.2 Antibodies 
First antibodies for histochemical immunostaining and Western blotting 
Table 2.2: First antibodies used for histochemical immunostaining. The antibodies were diluted according to instructions recommended by 
companies. 
 
First antibodies against: Company Cat.  No. 
Flag Sigma, Munich, Germany F3165 
MADH7  Abcam, Cambridge, UK ab5825 
β-Actin Sigma, Munich, Germany A 5441 
Phopho-Smad1 (Ser463/465)  Cell Signaling, Danvers, MA, USA 9511 
Phopho-Smad2 (Ser465/467) Cell Signaling, Danvers, MA, USA 3101 
Phopho-Smad3 (ser423/425) Cell Signaling, Danvers, MA, USA 9514 
α-Smooth muscle actin Sigma, Munich, Germany A 2547 
Smad3 Zymed, Karlsruhe, Germany 51-1500 
Smad2 Zymed, Karlsruhe, Germany 51-1300 
CD43  BD Pharmingen, California, USA 552366 
Proliferating cell nuclear antigen (PCNA) Sigma, Munich, Germany P 8825 
Cleaved caspase-3 (Asp175)  Cell Signaling, Danvers, MA, USA 9664 
Collagen type I (M-19) Santa Cruz Biotechnology, California, USA sc-8788 
 
Second antibodies for histochemical immunostaining 
Table 2.3: Horseradish peroxidase (HRP)-conjugated antibodies used for immunostaining. Dilutions of the antibodies were used according to 
instructions recommended by cpmpanies. 
 
Second antibodies  Company Cat. No. 
Goat anti-mouse  DAKO, Glostrup, Denmark A/S P 0447 
Rabbit anti-goat  DAKO, Glostrup, Denmark A/S P0449 
Swine anti-rabbit DAKO, Glostrup, Denmark A/S P0217 
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Second antibodies for Western blot analysis 
Table 2.4: Horseradish peroxidase (HRP)-conjugated antibodies used for Western blot analysis. Dilutions of antibodies were used according to 
instructions recommended by companies. 
 
Secondary  antibodies Company Cat. No 
Goat anti-mouse Santa Cruz Biotechnology, California, USA 2005 
Swine anti-rabbit Santa Cruz Biotechnology, California, USA 2004 
Rabbit anti-goat Santa Cruz Biotechnology, California, USA 2768 
Goat anti-rabbit Santa Cruz Biotechnology, California, USA 2301 
Bovine anti-mouse IgG AP Santa Cruz Biotechnology, California, USA 2389 
 
2.1.3 Reagents and material for animal experiments 
Table 2.7: Reagents and material for animal experiments 
 
Reagent and material Company Cat. No. 
Lipopolysaccharide (LPS) Sigma, Munich, Germany L-8274 
Carbon tetrachloride (CCl4) Fluka, Seelze, Germany 87032 
Mineral oil Sigma, Munich, Germany M-8410 
Syringe BD Plastipak, Dilsberg, Germany REF 300013 
Cannula (27 G x ¾ -Nr.20) 0.4mm x 19 mm BD Microlance TM 3,  Planegg-München, Germany REF 302200 
Glas capillaries Hilgenberg GmbH, Malsfeld, Germany 1410213 
Multi Ultra Tubes 0,2 ml Roth, Karlsruhe, Germany H561.1 
Nunc CryoTube Vilas 1,8 ml Nunc, London, UK 340711 
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2.1.4 Reagents for immunhistochemistry 
Table 2.8: Reagents for immunohistochemistry 
 
Reagent Company Cat. No 
3-(Triethoxysilyl)-propylamin (Silane) Merck, Darmstadt, Germany 821619.0100 
Mayers Hämalaun Merck, Darmstadt, Germany 1.09249.2500 
Malinol Waldeck GmbH, Münster, Germany 3C 242 
3,3'-diaminobenzidine tetrahydrochloride (DAB) DAKO, Hamburg, Germany S 3000 
Sirius red F3BA, 1A 280 Chroma 35780 
Saturated picric acid solution  Fluka 80456 
PBS Dublecco Biochrom AG, Berlin, Germany L182-50 
Tris (hydroxymethyl) aminomethane Merck, Darmstadt, Germany 1.08382.1000 
Gelatin type A Sigma, Munich, Germany G-7041 
Tri-Sodium citrat dihydrate Merck, Darmstadt, Germany A570148442 
Xylene J.T.Baker, Deventer Holland 108681 
Absolute ethanol House drugstore, medical clinical Mannheim, 
Germany 
 
Hydrogen peroxide Merck, Darmstadt, Germany K31856110335 
 
2.1.5 Reagents for preparation of protein lysates 
Table 2.9: Reagents for preparation of protein lysates 
 
Reagent and material Company Cat. No. 
Tris (hydroxymethyl) aminomethane Merck, Darmstadt, Germany 1.08382.1000 
Sodium chloride Sigma, Munich, Germany S-9625 
Deoxycholic acid.Na-salt Serva, Heidelberg, Germany 18330 
Sodium dedocyl sulfate (SDS) Roche, Penzberg, Germany 23262 
Nonidet P-40 Roche, Penzberg, Germany 1754599 
Complete (Protease inhibitor cocktail)  Roche, Penzberg, Germany 1697498 
Phosphatase inhibitor cocktail II Sigma, Munich, Germany P-5726 
liquid nitrogen   
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2.1.6 Protocol for RIPA buffer preparation 
Table 2.10: Components of RIPA buffer for 1000 ml 
 
Reagent Molarity For 1000 ml 
Tris (hydroxymethyl) aminomethane 20 mM 2.42        g 
Sodium chloride 150 mM 8.76        g 
Sodium dedocyl sulfate (SDS) 0,1 % (w/v) 1             g 
Deoxycholic acid. Na-salt (DOC) 0,5 % (w/v) 5             g 
Nonidet P-40 2 % (v/v) 20           ml 
 
pH 7.2, concentrated HCl 
Notice: Mix all salts together and adjust to pH 7.2. Finally add Nonidet P-40 and adjust again to pH 7.2.  
2.2 Animals 
All protocols for experiments with animals were carried out in full compliance with the guidelines for animal care and 
were approved by the Animal Care Committee from the German government. 
2.2.1  Origin of the FVB/N  strain 
The inbred strain FVB/NJ is available from the Jackson Laboratory. This strain is preferred for production of transgenic 
mice due to several unique characteristics. The pronuclei of the zygotes are large and easily visible making 
microinjection much easier. The strain has large litters with an average litter size of 9.5 pups/litter. It is favored to use 
inbred strains over hybrid F1 or F2 mice. Because after successful insertion of DNA into hybrid mice, extensive 
backcrossing is required to establish the mutation on an inbred background. Thus, using an inbred strain simplifies 
genetic manipulation and analysis. The Jackson Laboratory obtained FVB/N mice from the NIH in 1987 at F38.  
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Figure 2.3: The FVB/N strain. This strain was developed from an 
outbred strain of a Swiss stock selected for histamine sensitivity. The 
line was later identified to carry the Fv-1b allele (therefore its name) 
for sensitivity to the B strain of Friend leukemia virus. (Source: 
Jackson Laboratory) 
 
 
 
 
 
 
 
 
2.2.2 Origin of the CD-1 strain 
The CD-1 mouse was provided from the Charles River Laboratory and is officially designated Crl:CD-1 (ICR)BR. It is 
an albino animal that carries a black agouti coat color behind its albino gene and represents an outbred strain. Its origin 
is a group of progenitors consisting of two male and seven female albino mice from a noninbred strain (origin unknown) 
in the laboratory of de Coulon, at the Centre Anticancereux Romand, Lausanne, Switzerland. These animals were 
imported into the United States by Clara Lynch from the Rockefeller Institute in 1926, outbred and passed over to other 
institutions and commercial breeders from 1928 to the early 1950s. The CD-1 mouse represents a useful model for 
toxicological studies supporting drug development and product registration. 
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2.3 Bacteria 
The competent Escherichia coli stem DH5α purchased from Invitrogen, Karlsruhe, Germany was cultured for 
reproduction and transformation with plasmids. 
Cat. No. 18265-017 
Bacteria were cultured in liquid LB medium or on LB-agar plates containing suitable antibiotics for colony selection. 
LB-Medium 
Material 
LB Medium (Luria/Miller), Roth, Karlsruhe, Germany, Cat. No. X968.1 
Ampicillin 100 mg/ml, Mannheim, Germany, Cat. No. 10835269001 
Protocol 
1. Add 12.5 g LB Medium to 1000 ml dH2O. 
2. Autoclave at 121°C for 20 minutes. 
3. Cool the LB-medium to 60°C.  
4. Add 1 ml ampicillin (100 mg/ml) to reach an end concentration of 100 µg/ml. 
For agar plates add 20g agar (Gibco-BRL, USA, Cat. No. 30391/023) to the medium before autoclaving. After adding 
ampicillin pour thin layers (5mm) of LB-agar into each culture plate. 
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2.4 Plasmids 
A: Plasmid pcDNA3.1-Flag-Smad7 
Table 2.5: Characteristics of pcDNA3.1-Flag-Smad7 
 
Plasmid name pcDNA3.1-Flag-Smad7 
Plasmid size 6.689 kb 
Fragment of interest Flag-Smad7  
Restriction sites used BamHI-XhoI 
Smad7 insert size 1.3 kb 
Kindly provided by P. ten Dijke Division of cellular biochemistry, the Netherlands cancer 
institute, Amsterdam, the Netherlands 
 
 
 
 
Figure 2.1: Gene map of the plasmid pcDNA3.1-Flag-
Smad7 containing mouse Smad7 cDNA. Analytic 
restriction sites are indicated. CMV promoter: bases 232-
819; T7 promoter/priming site: bases 863-882; Multiple 
cloning site: bases 895-1010; pcFNA3.1/BGH reverse 
priming site: bases 1022-1039 ; BGH polyadenylation 
sequence: bases 1028-1252; f1 origin: bases 1298- 1726; 
SV40 early promoter and origin: bases 1731-2047; 
Neomycin resistance gene (ORF): bases 2136-2930; 
SV40 early polyadenylation signal: bases 3104-3234; 
pUC origin: bases 3617-4287 (complementary strand); 
Ampicillin resistance gene: bases 4432-5428 
(complementary strand); (Source: Modified from 
Invitrogen life technologies) 
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B: Plasmid U2 
Table 2.6: Characteristics of Plasmid U2 
 
Plasmid name U2 
Fragment of interest CRP promoter from human 
Plasmid size 8.2 kb 
Restriction site used SmaI 
Kindly provided by  S. Kanzler (Department of Medicine I, University of Mainz) 
 
 
 
Figure 2.2: Gene map of the 8.2 kb plasmid U2 containing the human C reactive protein (CRP)-promoter. (Source: S. Kanzler, Department of 
Medicine I, University of Mainz). 
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2.5 Cloning strategy to create CRP-Smad7  
In order to create CRP-Smad7 the plasmids U2 and pcDNA3.1-Flag-Smad7 harboring the human CRP-promoter and 
mouse Smad7, respectively were amplified. After cutting the plasmids at suitable sites using restriction enzymes, the 
fragments of interest were ligated as follows.   
2.5.1  Amplification of plasmids pcDNA3.1-Flag-Smad7 and U2  
Plasmid amplification was done in competent Escherichia coli DH5α cells. 
Material and reagents 
LB Medium  
Agar, Gibco-BRL 
Ampicillin 100 mg/ml 
1.5 ml microfuge tubes  
42° C water bath  
Ice  
37° C shaker 
Protocol 
1. Thaw competent cells (DH5α) on ice. 20–50 µl per tube. 
2. Add max. 1-2 µl of a ligation reaction (10 ng/µl plasmid pcDNA3.1).  
3. Mix very gently!  
4. Incubate the tubes on ice for 30 minutes.  
5. Heat shock the cells for 45 sec at 42° C.  
6. Place the tubes immediately on ice for at least 2 minutes.  
7. Add 950 µl of 2.5% LB-medium (100 µg/ml ampicillin) to each tube.  
8. Incubate for 1 hour at 37° C and shake vigorously.  
9. Spin down briefly and remove most supernatant (steps 9 and 10 are optional). 
10. Resuspend thecell pellet with the remaining LB medium in the tube by pipetting. 
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11. Plate out 50-100 µl of the suspension on a LB agar plate (1.25% LB-Medium, 2% agar) containing the 
appropriate antibiotic (100 µg/ml ampicillin).  
12. Incubate the plates at 37° C overnight. 
2.5.2 Preparation of bacterial preparatory cultures 
Protocol 
1. Add 10 ml of sterile LB-Medium to a 50 ml falcon tube. 
2. Pick one bacterial colony with an inoculation loop from the LB-Agar plate and transfer the bacteria to the liquid 
medium. 
3. Incubate the flask with shaking at 37° C overnight. 
2.5.3 Growth of bacteria 
Protocol 
1. Add 400 ml of LB medium to a sterile Erlenmeyer flask. 
2. Transfer 0.8 ml of a preparatory culture into the Erlenmeyer flask 
3. Incubate with shaking at 37° C overnight.  
2.5.4 DNA plasmid maxi preparation  
Plasmid-DNA preparation was carried out according to the “EndoFree Plasmid Maxi Protocol” (QIAGEN, Cat. 
No.12362). 
2.5.5  Measuring plasmid DNA concentration 
The concentration of plasmid DNA was measured at 260 and 280 nm using the RNA/DNA Calculator (Gene Quannt II, 
Pharmacia Biotech). 
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2.5.6 Plasmid restriction digestion analysis 
Restriction enzyme digestions were performed by incubating double-stranded DNA molecules with a suitable amount of 
restriction enzyme, in its respective buffer as recommended by the supplier, and at the optimal temperature for that 
specific enzyme. All restriction enzymes and buffers were purchased from Roche. Standard digestions included one unit 
of enzyme per 200 ng of DNA. 
2.5.7 Digestion of plasmid pcDNA3.1-Flag-Smad7 
To isolate the fragment Flag-Smad7 from the plasmid pcDNA3.1-Flag-Smad7, the plasmid was treated with XhoI and 
BamHI as follows: 
Protocol 
1. Plasmid-DNA 50-100  ng 
2. Restriction buffer B (10 x) 1.5        µl 
3. Restriction enzyme XhoI (10 U/µl)        1           µl 
4. Restriction enzyme BamHI (10 U/µl)    1           µl 
5. dH2O 15         µl 
6. Incubation at 37° C 2           h 
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2.5.8 Digestion of plasmid U2 
In order to ligate the fragment Flag-Smad7 into the plasmid U2 a SmaI (Roche, Mannheim, Cat. No. 656348)) 
restriction digestion of the vector was required: 
Protocol 
1. DNA 50-100 ng 
2. Restriction buffer A (10 x)  2          µl 
3. Restriction enzyme SmaI (10 U/µl)    1          µl 
4. Add dH2O 20        µl 
5. Incubation at 25° C 2          h 
 
2.5.9 DNA agarose gel electrophoresis  
For DNA agarose gel electrophoresis gel concentrations were chosen according to expected fragment sizes.  
Protocol 
1. Agarose gels of different concentrations are prepared by mixing agarose with an appropriate volume of 1 x TAE 
buffer and dissolving the agarose by heating the mixture in a microwave for 2-4 minutes. 
2. When the temperature reaches about 60° C, pour the gel onto a taped plate with casting combs in place. Allow 
the gel to polymerize for 1 hour. 
3. Remove the tape and the gel casting combs carefully and lay the gel in a horizontal electrophoresis apparatus. 
Pour 1 x TAE buffer until the agarose gel dives 1 cm under the buffer. 
4. Add DNA loading dye to each DNA sample, mix and load into the slots. 
5. Electrophorese the gel at 90 V for 30-60 minutes until the required separation is achieved. 
6. Place the gel for staining into ethidiumbromide solution (0,5µg/ml TAE buffer) for about 30 minutes. 
7. Wash the gel with water and visualize DNA fragments in a UV light box (MWG Biotech, Germany). 
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2.5.10 Dephosphorylation of DNA fragments 
Cleavage of the phosphate group 
To avoid religation of digested vector DNA, 5´-phosphate groups of restriction fragments are treated with alkaline 
phosphatase (Roche Mannheim, Cat. No. 1758250, 1000 U) according to the following protocol: 
Protocol 
1. 100 ng digested plasmid e.g. U2 10 µl 
2. 10 x dephosphorylation buffer 2  µl 
3. Alkaline phosphatase (1 U/µl) 2  µl 
4. dH2O 6  µl 
5. Incubation at 37°C 15 min 
 
2.5.11 Purification of plasmid U2  
Purification of plasmid U2 was performed with a QIAquick PCR purification kit (Cat. No. 28104). This protocol is 
designed to purify single- or double-stranded DNA fragments from enzymatic reactions. Fragments ranging from 100 bp 
to 10 kb are purified from primers, nucleotides, polymerases, and salts using QIAquick spin columns in a 
microcentrifuge.  
2.5.12 Treatment of the fragment Flag-Smad7 with Klenow fragment 
Klenow fragment was purchased from Roche, Cat. No. 008 412 001, 500 U (2 U/ µl) 
The Klenow fragment (Mr 75000) of DNA polymerase I is used for partial or complete filling of 3´recessed ends (e.g. 
after restriction enzyme digestion). It carries a 5´→3´polymerase and a 3´→5´exonuclease activity of intact DNA 
polymerase I, but lacks the 5´→3´exonuclease activity of the native enzyme. The enzyme catalyzes the addition of 
mononucleotides from deoxynucleoside-5´-triphosphates to the 3´-hydroxyterminus of a primer/template DNA. This 
property can be used to synthesize DNA complementary to single-stranded DNA templates. 
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Protocol 
1. Template DNA 1 µg  
2. Nucleotides*, final concentration  1 mM of each dNTP* needed 
3. 10 x Filling buffer 2 µl 
4. Klenow fragment 1 U 
5. Add dH2O up to  20 µl 
6. Incubation at 37° C 15 min 
 
* Add dNTP`s as needed according to the sequence only. Filling buffer (10 x): 500 mM Tris (pH 7.5), 100 mM MgCl2, 10 mM DTT, 500 µg/ml 
BSA. Inactivation of the enzyme is carried out by adding 2 µl 0.2 M EDTA (pH 8.0) and/or heat to 65°C for 10 minutes 
2.5.13 Elution of DNA fragments from agarose gel slices  
DNA fragments were eluted from Seakem agarose gels using the “freeze squeeze” method according to Thuring et al., 
1975 [117] . 
2.5.14 Test ligations and transformations (FERAY) 
To test whether dephosphorylation has worked, religation of the vector was checked. For this, the “LigaFast TM Rapid 
DNA Ligation System”, from Promega (Cat. No M8225, 500 Weiss units) was used. 
Protocol 
1. Digested and dephosphorylated plasmid e.g. U2  1 µl = 100 ng 
2. T4 DNA ligase                                                      1 µl = 3 U         
3. 2 x rapid ligase buffer 5 µl 
4. H2O (nuclease-free) 3 µl 
 
Incubate the reaction at room temperature for 15 minutes or over night at 16° C.  
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Size-fractionate the digestion mix on a 0.8% agarose gel along with the phosphorylated digested vector and compare the 
patterns. If you see linearized plasmid DNA dephosphorylation has worked. 
Transformation of religated vector could be used as an alternative to assess success of dephosphorylation. 
Protocol 
1. Digested and dephosphorylated plasmid U2       1 µl = 100 ng 
2. T4 DNA ligase                                                    1 µl = 3 U        
3. 2 x rapid ligase buffer 5 µl 
4. H2O (nuclease-free) 3 µl 
5. Incubation for15 minutes at room temperature  
 
For transformations, 1 µl of the ligation mix is added to 50 µl DH5α competent E. coli cells. These were plated on LB-
Agar plates containing the appropriate antibiotics (see transformation of competent cells). After incubation at 37° C 
overnight, the number of colonies on each plate is counted. Dephosphorylation should reduce transformation efficiency 
of a linear plasmid by a factor of at least 50. 
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2.5.15 Ligation of the DNA fragment Flag-Smad7 into plasmid U2 
The ligation was carried out by using “LigaFast TM Rapid DNA Ligation System” (Promega, Cat. No. M8225, 500 
Weiss units). 
Protocol 
1. Assemble the following reaction in a sterile microcentrifuge tube: 
            Vector DNA (plasmid U2)                       100 ng (1 µl) 
            Insert DNA (Flag-Smad7)                        33   ng (1 µl) 
            2 x Rapid Ligation Buffer                         5    µl 
            T4 DNA Ligase (Weiss units)                   3    U 
            Nuclease-free water to final volume of    10   µl 
 
2. Incubate the reaction at room temperature for 15 minute for blunt-end ligations. 
 
Different concentrations (100, 20, 10 and 5 ng) of the plasmid U2 were used. Ligations were transformed into competent 
E. coli DH5α separately (see 2.7.1). Selected clones were picked up sterilely from LB-Agar plates and amplified in 10 
ml LB-medium culture under shaking at 37°C overnight. For clone screening 3 ml culture were used for plasmid 
isolation using QIAGEN Plasmid Mini preparation Kit (Cat. No 12123). 
Afterwards an analytical restriction analysis was performed. In order to obtain up to 500 µg endotoxin-free plasmid 
DNA for enzymatic reactions, EndoFree Plasmid Maxi Kit was used (QIAGEN-tip 500, Cat. No.12263).  
The resulting plasmid was named CRP-Smad7. 
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2.6 DNA sequencing 
Generated plasmids were checked by sequencing. An ABI310 sequencer and “ABI PRISM BigDye Terminator Cycler 
Sequencing Ready Reaction kit” with AmpliTaq® DNA polymerase, FS (PE-Applied Biosystems, Weiterstadt, 
Germany) was used for sequencing reactions. 
1000 ng double stranded plasmid DNA/PCR product served as templates. The following primers were obtained from 
MWG-Biotech AG (Ebersberg) to sequence CRP-Smad7. 
Table 2.11:  Primers for CRP-Smad7 DNA sequencing 
    
Designation Region Sequences 
SmaI-sense 50 bases distance from SmaI restriction site of 
plasmid U2 
5`- GTG AGG GGA TAG ATC 
TGT GTG-3` 
StyI-sense 195 bases distance from 3`end of plasmid Flag-
Smad7 
5`-GCC TAC AGC CTG CAG 
CGG CCC-3` 
 
The sequencing reaction was performed as follows. 
Protocol 
1. Big Dye Terminator premix                8         µl 
2. Primer 40       ng 
3. DNA template                                      1,000  ng 
4. Add H2O                                              20       µl 
 
Cycling conditions for 25 cycles: 
Denaturation  96° C 1 min 
Denaturation 96° C 10 sec 
Annealing 50° C  5 sec 
Elongation 60° C  4 min 
Cool down 4° C ∞ 
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To remove excess of dye terminators, the product was purified with a Centri Sep Spin Column (PE-Applied Biosystems, 
Weiterstadt, Germany) and subsequently dried in a speed vacuum system.  
Centri-Sep spin columns from Princeton Separations (P/N CS-901), are recommended. See manufacturer’s instructions 
and User Bulletin Number 20 for more details. 
Then each sample was resuspended in 25 µl of TSR (template suppression reagent, PE-Applied Biosystems, Weiterstadt, 
Germany) and denatured at 95° C for 2 min. Finally the sample was loaded into the capillary with a 30 second injection 
time at 2,000 V. 
After purification of the DNA, sequence data were analysed by ABI Prism Sequencing Analysis version 3.0.1b3 
software 
2.7 Transfection and stimulation of CRP-Smad7 in vitro 
Material 
FuGENE-6 (Roche, Cat.No 1814443) 
Lipopolysaccaride (LPS; L-8274; SigmaChemicals, Heidelberg, Germany) 
Interleukin-1β (recombinant human IL-1β; Chemicon; IL038 ) 
Interleukin-6 (recombinant IL-6; Chemicon; IL006) 
HepG2 cells (human liver carcinoma ) 
DMEM (Dulbecco's Modified Eagle Medium) 
Streptomycin 
Penestrep 
L-Glutamine 
Protocol 
Transfection using the FuGENE 6 reagent was performed as described by the manufacturer.  
Stimulation of CRP-Smad7 was carried out by exposing the cells to either 100 ng/ml LPS, or 10 ng (100 U) /ml IL-6 
plus 20 ng (200 U) /ml IL-1β, for 24 h. Control cells were left untreated. 
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2.8 RT-PCR 
2.8.1 Isolation of total RNA from animal tissue 
Total RNA from mouse liver tissue was isolated using the RNeasy Protect Mini Kit (QIAGEN, Cat. No. 74124). The kit 
provided an RNAlater RNA stabilization reagent to protect the RNA from degradation.  
Material 
RNeasy Protect Mini Kit (QIAGEN, Cat. No. 74124) 
Mortar and pestle 
20-gauge needle and syringe 
Nunc CryoTubeTM Vilas 1.8 ml (Nunc, London, UK, 340711). 
2.8.2 Omniscript reverse transcription 
Material 
Omniscript RT Kit (50) (QIAGEN, Cat. No. 205111) 
RNase inhibitor  
Perkins Elmer 9700 Thermal Cycler 
Protocol 
For reverse transcription of total RNA follow the protocol recommended by Omniscript RT Kit (50) (QIAGEN, Cat. No. 
205111 
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2.8.3 Polymerase chain reaction (PCR) to genotype transgenic mice: 
To genotype CRP-Smad7 transgenic offsprings an automated cycler (PE 9700 Thermal Cycler) was used. 
As templates 120 ng of the following double stranded DNAs were used: 
• Plasmid U2 after reception of Flag-Smad7 fragment (CRP/Smad7)       
• Mouse genomic DNA                                                                        
 
Primers used were designed to flank a region of the sequence of Smad7. After a PCR reaction a specific 550 bp product 
was expected. Primers as indicated were synthesized by MWG Biotech, Ebersberg, Germany. 
 
Designation Region Sequences 
CRP-sense C Correspond to the region beginning with nucleotide 
number 18181 on human CRP gene bank data  
5`- AGA CTG TAT GAA CAG 
AAC AGT GG-3` 
Smad7 –antisense C Correspond to the region beginning with Nucleotide 
number 1770 on mouse Smad7 gene bank  
5`-GGA CTC CAC GGC CTG 
AAG-3` 
 
A mixture of dATP, dCTP, dGTP and dTTP with a final concentration of 10 mM of each triphosphate was used as 
working solution for all PCR reactions. Deoxynucleotides were purchased from Roche, Mannheim, Germany.  
Taq DNA polymerase was provided from Amersham Pharmacia Biotech, Freiburg, Germany.  
 
The following protocol was used for PCR reactions: 
1. Let the frozen components thaw on ice and work on ice throughout. 
2. Prepare a master mix  
3. Vortex briefly the mix and distribute it in 0.2 ml PCR reaction tubes. 
4. Add DNA template to each PCR tube. 
5. Add the enzyme Taq DNA polymerase as the last component to each reaction. 
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Pipetting plan 
Table 2.14: Pipetting plan 
 
Component Amount 
Mg2+  containing 10 x buffer 10 mM 2.5   µl 
DNA Template 120  ng 
Downstream primer 5      pmol 
Upstream primer 5      pmol 
Deoxynucleotide mix (10 mM) 0.5   µl 
Taq DNA polymerase 0.5   µl 
 H2O up to 25    µl 
 
A thermal Cycler PE 9700 (Perkin/Elmer USA) was programmed as below program for 35 cycles. 
 
PCR step Reaction time  Temperature 
Preheat 5 minutes 95° C 
Denaturation  1 minute 95° C 
Annealing  30 seconds 56° C 
Extension 1 minute 72° C 
Extension of supposedly  loop  7 minutes 72° C 
Cool down ∞ 4° C 
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2.9 Histopathology analysis 
2.9.1 Immunohistochemistry 
The basic principle of any immunochemical technique is that a specific antibody will combine with its specific antigen 
to give an exclusive antibody-antigen complex. 
A specific antibody derived from an immunized animal recognizes and binds to specific amino acid sequences (epitopes) 
of its antigen. With the help of an e.g. horseradish peroxidase (HRP)-conjugated second antibody it is possible to detect 
specific antigen-antibody complexes.  
2.9.2 Fixation and blocking of tissue in paraffin 
Protocol 
1. Incubation of tissue samples in 4% formaldehyde (10% formalin) for 12-24 h. 
2. Remove the formalin and incubate in distilled water. 
3. Ethanol 70% 2 x 4 h. 
4. Ethanol 96% 2 x 4 h. 
5. Ethanol absolute 2 x 4 h. 
6. Xylene 3 x 2.5 h. 
7. Liquid paraffin at 60° C 2 x 4 h. 
8. Blocking of the tissue in a cassette. 
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2.9.3 Preparing and coating of slides with silane 
Protocol 
1. Incubate the slides 5 minutes in acetone. 
2. Dry the slides at 60° C in a drying chamber. 
3. Incubate the slides in a mix of 3-(Triethoxysilyl)-propylamin and acetone in a relation of 1:10. 
4. Immerse the slides in acetone 2 x 3 minutes. 
5. Immerse the slides in distilled water 1 x 3 minutes. 
6. Dry the slides at 60° C in a drying chamber overnight. 
Cutting of section 
Cut the tissue section 4 µm thick and incubate at 37° C overnight. 
2.9.4 Picro Sirius red staining   
Sirius red staining is a method to detect collagen fibers. As a result of unbalanced tissue repair, fibrotic tissues 
synthesize increasing amounts of collagen fibrils. The difference to healthy can be visualized by Sirius red staining.  
Material 
1N HCl 
NaOH 
Xylene  
Ethanol 100%, 95% and 70% 
Distilled water      
Formalin fixed and Paraffin embedded tissue section 5 µm thick 
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Reagents for 0.1% Picro-sirius red solution: 
 
1. Sirius red F3B        0.5 g 
2. Add Saturated aqueous picric acid  500 ml
3. Adjust pH 2 with NaOH  
4. Keep the solution for 6 months at 4° C 
 
Protocol 
Deparaffinization: Incubate the sections 40min at 60° C. 
Deparaffinize with xylene 3 x 5 minutes. 
Dehydration through descending ethanol: 100% 1 x 2 minutes. 
95% 1 x 2 minutes. 
70% 1 x 2 minutes. 
Hydration: Running water for 1 minute. 
Staining: Dip the sections into 0.1% Picro Sirius red solution for 1 h. 
Differentiation: 0.01 N HCl for 2 minutes. 
Wash: Running water 1 x 5 minutes. 
Dehydration through ascending ethanol: 95% 2 x 10 seconds 
100% 2 x 10 seconds 
Saving the tissues by conservation: xylene 2 x 10 sec. and cover the section with malin oil and 
cover glass. 
Microscopy:  Use a bright field microscope.  
 
Chapter 2 Materials and methods 51 
 
2.9.5 Immunohistochemical staining  
This protocol is based on immunostaining protocol recommended by “Cell Signaling” with modifications as indicated 
below: 
Antigen unmasking using microwave: 
1. Heat sections up to 95° C in 10 mM sodium citrate buffer pH 6.0 or EDTA pH 8 (depends on the antibody in 
use), then maintain the temperature at a sub-boiling temperature for 9 minutes (2 min 200 watt and 7 min. 150 
watt).  
2. Cool sections on the bench top for 35-40 minutes to reach a temperature of 37° C.  
3. Wash sections in dH2O three times for 5 minutes each. 
Removing of endogenous peroxidase 
Note: At this step work in a moist atmosphere by using a moist box. 
4. Cover the tissues with some drops of “Peroxidase Blocking Reagenz” (DAKO, Cat. No. S2001) for 30 minutes. 
Preparation and application of peroxidase substrate 3,3'-diaminobenzidine tetrahydrochloride 
(DAB) 
5. Prepare substrate by dissolving 1 tablet of DAB in 16.6 ml 0.05 M Tris (hydroxymethyl) aminomethane, pH 7.6 
(keep in dark). 
6. Filter with filter paper.  
7. Add 12 µl H2O2 to filtrate.  
8. Cover sections by pipetting 200 µl of the substrate to each sample. 
9. As soon as the color turns weakly brown, stop the reaction by immersing sections in running water for 5 minutes. 
Counterstaining 
10. Immerse the sections in Mayers Hämalaun solution for 30 seconds 
11. Wash the sections in running water for 10 minutes. 
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2.10  Western blot 
Western blot was used to analyse protein expression.  
2.10.1 Production of protein lysate from tissues by homogenization 
Material 
mortar 
liquid nitrogen 
syringe with 0.75 mm needle 
Protocol 
1. Chill the mortar with liquid nitrogen. 
2. Grind the tissue with mortal while adding nitrogen. 
3. Mix a little grinded tissue (a spatula tip) with 500 µl RIPA (containing complete protease inhibitor) + 
(phosphatase inhibitor cocktail II). 
4. Homogenize the tissue mix using a 0.75 mm needle. 
5. Centrifuge at 14000 rpm for 10 minutes. 
6. Remove the supernatant.  
7. Measure the protein concentration with program CD Assay Biorad at 690 nm by means of Wallac Victor-1420 a 
multilabel, multitask plate r 
2.10.2 Measurement of protein concentration 
Protein concentrations were determined using the Dc Protein Assay (Bio-Rad Laboratories) based on the Lowry assay. 
Each sample was pipetted threefold into a microtiterplate and measured. The absorbance was read at 690 nm using a 
spectrophotometer (Wallac 1420 Victor, Wallac, Turku, Finland). Protein concentrations were calculated as an average 
value of three counts and related to the protein standard curve and blank value of RIPA. 
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2.10.3 SDS gel electrophoresis  
Material 
NuPAGE MOPS SDS running buffer (20 x) 500 ml (Invitrogen, NP0001) 
NuPage LDS sample buffer (4 x), 10 ml (Invitrogen , NP0007) 
SeeBlue (Invitrogen. LC5925) 
Dithiothreitol (DTT, reducing agent, Sigma, D-9779,)  
NuPAGE 4-12 % Bis-Tris Gel 1.5 mm x 10 well (Invitrogen, NP0335BOX) 
NuPAGE transfer buffer (20 x) 1 L (Invitrogen, NP0006-1) 
Nitrocellulose membrane sheet, 0.5 micron, 33 cm x 3 m roll (Pierce, Pierce, Woburn, MA, U.S.A.Prod # 88018) 
Super Signal west dura stable peroxidase buffer (Pierce, Prod # 1856146) 
Super Signal west dura luminol/enhancer solution (Pierce, Prod # 1856145) 
Nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany,10401180) 
Whatman 3 MM (Schleicher & Schuell, 10426693) 
Top-Block (Aluminum replacement, Fluka, Biochemika, 37766) 
Protocol 
Preparing samples for denaturing NuPAGE® gel electrophoresis 
1. Preheat the NuPage Lsample buffer (4 x) to 37 °C 
2. Pipet 30 µg of each protein in a 1.5 ml Eppendorf tube 
3. Ad up to 27.5 µl dH2O 
4. Ad 2.5 µl 1 M DDT 
5. Add 10 µl preheated NuPage SDS sample buffer (4x) 
6. Vortex and centrifuge shortly 
7. Heat to 70° C on a heat plate for 10 minutes while shaking 
8. Centrifuge shortly 
9. Put 40 µl of each sample per well on a NuPAGE 4-12% Bis-Tris Gel  
10. Use 6 µl of SeeBlue as protein marker 
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11. Separate the proteins in the XCell SureLock™ Novex Mini-Cell (Invitrogen) at 100-150 V for 90 minutes. 
 
For NuPAGE® Gel Electrophoresis and transfer of the proteins on a nitrocellulose membrane see “Instruction Manual 
NuPAGE® Technical Guide General Information” and protocols for using the NuPAGE® electrophoresis system. 
Transfer the proteins from a gel on a NC-membrane at 50-65 V and 300 mA for 2 h. 
 
Figure 2.4: Diagrammatic construction of one gel and two gels Western Blot arrangements.   
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2.10.4 Detection of antigens  
1. Wash the NC-membrane with 25 ml TBS for 5 minutes 
2. Incubate the transfer membrane with 15 ml of 5% Bio-Skim Milk in TBST for later treatment with monoclonal 
antibodies (or 5% Top-Block in TBST for later treatment with polyclonal antibodies, albumin replacement, 
Fluka) while shaking for 1 hour 
3. Incubate the transfer membrane overnight in 5% Bio-Skim Milk in TBST with a first antibody at 4° C while 
shaking 
4. Wash three times with TPST, 5 minutes each 
5. Incubate the transfer membrane in 5% Bio-Skim Milk in TBST with second HRP-conjugated antibodies 
6. Wash three times with TBST, 5 minutes each 
7. Mix 350 µl peroxide buffer with 350 µl luminol/enhancer solution 
8. Distribute the mix equally on the transfer membrane  
9. Incubate for 5 minutes 
10.  Develop the transfer membrane using the Lymi-Analyser as soon as you see a colour change. 
2.11 Analysis of hydroxyproline  
Hydroxyproline and proline are main components of collagen. The prime structure of collagen consists of glycine-X-Y, 
where proline substitutes X and hydroxyproline Y. Hydroxyproline is built of proline in the presence of vitamin C. 
Hydroxyproline gives strength to the collagen molecule and its level increases during fibrosis. For this reason it is a 
useful marker of fibrosis.  
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2.11.1 Hydroxyproline assay 
 
Material 
Nitrogen and nitrogen container 
Special glass tube (Schott Duran 12 x 100, 26 135 11 55, Roth, K248.1) 
1.9 ml reaction tube (Roth, 7550.1) 
Microtube Tough-Tags, sticker (Roth, 1.5-2 ml Tubes) 
Analysis balance  
Incubator 110° C 
Water bath 50-56° C 
Spatula 
Filter paper 
50 ml Erlenmeyer flask  
Spectrophotometer, Pharmacia Biotech, Ultraspec 2000 
Filter papers, Folded MN 615, ¼ 9 diameter (Machery Nagel, 531009) 
Glas funnel 
Reagents 
37% concentrated HCl (Merck, 1.00317.1000) 
4-(Dimethyl-amino) benzaldehyde, Ehrliche`s Reagenz (Sigma, D2004-100G). 
Chloramine-T-hydrate (Sigma, C9887-250G) 
Isopropanol (Merck, 1.09634.2500) 
Perchloric acid 70% (Fluka, 77230) 
Natriumacetat 
Citric acid  
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Protocol 
Refer to Jamall et al. 1981, Boigk et al. 1997 [9]. 
 
Note: Spatula and special glass tubes (Schott Duran) are prechilled in nitrogen. Do not let the pulverized tissues be 
thawed before mixing it with 6N HCl. To make 6N HCl mix 49.7 ml (12N, 37% concentrated HCl) with 53.3 ml H2O 
 
1. Put at least 50 mg of pulverized liver tissues in cold special glass tube (Schott Duran) using a chilled spatula and 
add 1 ml 6N HCl  
2. Incubate at 110° C overnight for 16 hours in an incubator 
3. Vortex for 10 seconds 
4. Filtrate the homogenate with filter paper 
5. Pipette 2 x 30 µl of the filtrate in 1.5 ml Eppendorf tubes for double measurements 
6. Add 10-30 µl of methanol to the filtrate 
7. Vortex briefly 
8. Let the reagent dry for 30 minutes in a heat block at 37° C under nitogen gas access. 
9. The pellet can be stored at -20° C  
10. Prepare a Hydroxyproline standard sample as described below 
 
Note: Hydroxyproline (HP) stock solution is 1 mg/ml in 50 % Isopropanol. Dilute the HP 
stock solution 1:100 in 50% Isopropanol to reach a concentration of 10 µg/ml. 
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Standard 
Nr. 
Hydroxyproline 
 µg 
HP working solution (10µg/ml) 
 µl 
50 % Isopropanol  
 µl 
0 Blank value 0 500 
1 0.1 10 490 
2 0.2 20 480 
3 0.3 30 470 
4 0.4 40 460 
5 0.5 50 450 
6 0.7 70 430 
7 0.8 90 410 
8 1.1 110 390 
9 1.3 130 370 
10 1.5 150 350 
11 1.7 170 330 
 
11. Treat the hydroxproline standards from Step 13 like samples 
12. Dissolve the pellet in 1 ml of 50% Isopropanol 
13.  Pipette 100 µl of freshly prepared 0.84% Chloramin-T solution to 0.5 ml of the sample solution 
14. Vortex briefly 
 
0.84 % Chloramin-T solution  Reagant  Volume for 100 ml 
(fresh) Chloramin T 840 mg 
 Cloramin-T Puffer 60.5 ml 
 Isopropanol 100% 39.5 ml 
 
 
Chloramin-T buffer:                 Reagent  Concentration mM 
pH 6 (2 N sodium hydroxyd) Sodium acetate 42 
                                              
 
Citric acid 2.6 
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15. Incubate for 10 minutes at room temperature 
16. Add 0.5 ml of freshly prepared Ehrlich´s reagent solution. 
 
Ehrlich´s Reagent solution  Reagant  Volume for 500 µl 
(Fresh) Ehrlich´s Reagent 124 mg 
 70% perchloric acid 135 µl 
 Isopropanol 100% 365 µl 
 
 
17. Incubate in awater bath at 50-56 °C for 90 minutes. 
18. Measure the absorbance of all HP standards and samples at 558 nm against a blank value. 
19. The HP value is calculated in µg/g liver. 
2.12 Hyaluronic acid assay 
Serum hyaluronic acid (HA) levels can be elevated in various liver diseases, e.g. liver fibrosis and cirrhosis, due to 
decreased hepatic removal and/or increased hepatic production. Increased HA levels have shown a better correlation 
with the degree of histopathological damage than conventional liver function tests including ALT/GOT, alkaline 
phosphatase and bilirubin. HA levels have also been shown to be an early marker of liver damage from toxic agents such 
as ethanol, acetaminophen, and bacterial lipopolysaccharide. Changes of the sinusoidal endothelial cells (SEC) in 
response to these agents precede pathological changes of the hepatocytes. 
Protocol 
Hyaluronic acid assay 
The concentration of hyaluronic acid in the serum of mice was determined with a Hyaluronic Acid (HA) Quantitative 
Test Kit (Corgenix, Colorado, USA). Absorbance at 450 nm was determined using a Victor 1420 Multilable Counter 
spectrometer (Wallac, Wellesley, USA). 
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2.13 Measurement of liver enzymes in the serum of mice 
To measure the concentration of serum enzymes ca. 1 ml of blood was taken from anaesthetized mice by a needle prick 
into their eyes. Serum was produced by centrifuging the blood at 3000 rpm for 10 min. Aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) and alkaline phosphatase (AP) concentrations were determined by using the 
VITROS Chemistry Products Calibrator Kit 3 and VITROS Chemistry Systems (Ortho-Clinical Diagnostics). 
2.14 Induction of fibrosis with CCl4 and stimulation of CRP-Smad7 
construct with LPS 
Animals were divided in four groups e.g.  CCl4 group, LPS group, CCl4 + LPS group and control group in an experiment  
arranged for 8 weeks. In order to keep small  mortality rate of  animals in the CCl4 group  a pretreatment with CCl4 was 
necessary . This was achieved  by i.p. of 12.5% CCl4 in mineral oil two times/week followed with  one week rest period.  
Thereafter they were treated with 25% CCl4 in mineral oil two times /week for  entire 8 weeks. The LPS group were 
injected i.p. with 10 µg LPS in PBS/ 25 g mice three times/week.. After six weeks the LPS dose was increased up to 25 
µg LPS in PBS/ 25 g mice for entire further two weeks. The control mice for CCl4 group were treated with 50 µl mineral 
oil two times/week. for 8 weeks. To limit mortality, experimental mice determined for CCl4 and LPS treatment have 
been injected at alternate days with both. 
2.15 Statistical analysis 
At least 20 animals were used for each group investigation. The data presented are representative for 3 or more similar 
experiments. The results were expressed as means ± standard deviation (SD), and statistical analysis was carried out 
using Student t-test for paired data. Differences at P< 0.01 were considered to be significant. 
Notification: Graphic designation with one star (*) refers to statisticcal analyse between the FVB mice and S7tg mice in 
CCl4 + LPS treated group. Two stars (**) refer to statisticcal analyse between the FVB mice and S7tg mice in CCl4 
treated group and three stars (***) refer to statistical analyse between the CD-1 mice and S7?E1 mice in CCl4 treated 
group 
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3 Results  
3.1 Cloning of CRP-Smad7  
In order to investigate the antifibrotic effect of Smad7 on liver fibrosis, CRP-Smad7 transgenic mice were generated. 
For that purpose a plasmid CRP-Smad7 was created. 1.3 kb mouse Smad7 cDNA was cloned into a vector under control 
of the human C-reactive protein promoter. In order to simplify the detection of transgenic derived Smad7 in protein 
lysates a 42 bp long Flag-tag was linked to Smad7. The mouse Flag-Smad7 cDNA deriving from the 6.689 kb 
pcDNA3.1-Flag-Smad7 plasmid (friendly gift of P. ten Dijke) was cut using the BamHI and XhoI restriction sites. The 
resulting sticky ends were completed using the Klenow fragment achieving a smooth end. To subject the mouse Smad7 
cDNA fragment (Flag-Smad7 insert) under control of the human C-reactive protein, a 8.2 kb plasmid, U2 (friendly gift 
from department of Medicine I, University of Mainz, Dr. S. Kanzler) harboring a human CRP promoter fragment, was 
digested at its SmaI restriction site. After that the Flag-Smad7 fragment was inserted into the promoter site as follows 
(figure 3.1). 
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Figure 3.1: Diagram showing the cloning strategy for CRP-Smad7 
 A: The Fragment Flag-Smad7 was obtained by digestion of pCNA3.1-Flag-Smad7 using BmaHI and XhoI. The digestion sites were extended 
using Klenow fragment; B: In order to clone the fragment Flag-Smad7 into the plasmid U2 it was digested with SmaI. 
 
After ligation of the Flag-Smad7 fragment into the plasmid U2, the samples were transformed into competent E. coli 
DH5α cells. Colonies were picked up sterilely from the agar plate and amplified in 10 ml LB-medium. For clone 
screening 3 ml of transfected competent cells (DH5α) were prepared using the QIAGEN Plasmid Mini preparation Kit. 
The isolated DNA was restricted by XbaI and subjected to agarose gel electrophoresis (figure 3.2). The expected 
fragments of 6.3, 2.1 and 1.1 kb could be visualized on an agarose gel indicating the successful cloning of CRP-Smad7. 
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Figure 3.2: Control gel to check CRP-Smad7. Four different clones (PI to PIV) were checked. After plasmid mini preparation the DNA was 
digested with XbaI. Three different fragment sizes i.e. 6.3. 2.1 and 1.1 kb were expected.  
 
Insertion of Flag-Smad7 increased the size of U2 by 1.3kb. The resulting plasmid CRP-Smad7 contained 9.5 kb. Figure 
3.3 shows a gene as well as a restriction map of CRP-Smad7. 
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Figure 3.3: Restriction map (A) and gene map (B) of CRP-Smad7. 
 
Sequence analysis confirmed successful insertion of the fragment Flag-Smad7 into the vector U2 (figure 3.4). 
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Figure 3.4: Sequencing of CRP-Smad7. The arrows indicate the ligation sites between Flag-Smad7 and the original U2 vector.  
3.2 Smad7 expression in HepG2 cells  
To prove the biological activity of CRP-Smad7 HepG2 cells were transfected with plasmid DNA using FuGENE. 
Expression of Smad7 was stimulated by treatment of the cells with IL-1 (10 ng/ml), IL-1 + IL-6 (30 ng/ml) and LPS 
(100 ng/well) for 24 h. Afterwards cell lysates were analysed by immunoblotting as shown in figure 3.5. Whereas IL-1 
was not able to stimulate the CRP promoter, co-induction of the CRP promoter with both, IL-1 and IL-6, as well as LPS 
application resulted in the stimulation of the CRP promoter. Flag-Smad7 expression was determined by Western blotting 
and immunostaining. A lysate obtained from HSCs infected with Adenovirus-Smad7 (AdSmad7) in cell culture served 
as a positive control. 
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Figure 3.5: Expression of Flag-Smad7 in HepG2 cells transfected with CRP-Smad7. Expression was induced in vitro by treatment with either 
IL-1 (10 ng / ml), IL-1 (10 ng/ml) + IL-6 (30 ng / ml) or LPS, 100 ng / well, for 24 h. Smad7 expression (46,428 kDa) was visualized by 
Western blotting using polyclonal goat anti-Smad7 antibodies. (abcam; ab5825;2 µg/ml). A lysate of HSCs infected with AdSmad7 was used as 
a positive control. As a loading control, the blot was reprobed with monoclonal mouse anti-β-actin antibodies (SIGMA;A5441;1:10000). The 
protein load per well was 20 µg. Abbr. ut = untreated., FCS = focal calf serum. 
 
3.3 Generation of CRP-Smad7 transgenic mice 
3.3.1 Microinjection of CRP-Smad7 into fertilized eggs of FVB/N mice  
Transgenic mice were generated according to standard procedures (Hogan, B. L. M., F. Costatini, and E. Lacy. 
Manipulating the Mouse Embryo. A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor 
Laboratory, 1986.) by microinjection of vector-free CRP-Smad7 DNA (Figure 3.6) into fertilized eggs of FVB/N mice. 
By transformation 70 potentially transgenic mice were generated. By PCR 9 CRP-Smad7 transgenic mice founders 
could be verified. Finally, two positive transgenic founders survived and built two stable lines (2408 and 2448). 
Genotyping of transgenic mice was done by analysing DNA from tails of 4 weeks old offspring by PCR and subsequent 
gel electrophoresis analysis (figure 3.7). Positive transgenic offspring were mated to build stable transgenic lines.  
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Figure 3.6: Microinjection of CRP-Smad7 into fertilized eggs of a superovulated female FVB/N mouse.  
 
 
 
Figure 3.7: Schematic presentation to show the creation of CRP-Smad7 transgenic mice. 
 
The transmission of CRP-Smad7 was differently between new generations of line 2408 and 2448. Whereas CRP-Smad7 
construct was distributed evenly between offspring from line 2448, it was transmitted predominantly by female mice of 
line 2408 as shown in figures 3.8 and 3.9. 
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Figure 3.8: Pedigree of CRP-Smad7 transgenic mice line 2408. CRP-Smad7 was transmitted mainly by female transgenic animals. 
 
 Indications: female wild type            ,     male wild type             , 
 
                     female transgenic           ,     male transgenic           . 
Chapter 3 Results 69 
 
 
 
 
 
 
 
 Figure 3.9: Pedigree of CRP-Smad7 transgenic mice line 2448. The diagram indicates even distribution of CRP-Smad7 within different 
generations. 
 
 Indications: female wild type            ,     male wild type             , 
 
                     female transgenic           ,     male transgenic           . 
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3.4 Genotyping of CRP-Smad7 transgenic mice 
In order to genotype transgenic offspring mouse tail DNA was isolated 4 weeks after birth and was analysed by PCR. 
Primers used are listed in Table 3.1. The expected PCR fragment using the CRP-sense C and Smad7 antisense C primers 
is 550 bp long. The result was checked by subsequent agarose gel electrophoresis. Figure 3.10 shows examples of the 
results of transgenic offspring as well as CRP-Smad7 negative animals. 
 
Table 3.1: Primers used to genotype CRP-Smad7 transgenic mice. 
 
Designation Region Sequences 
CRP-sense C Correspond to the region beginning with nucleotide number 18181 on 
human CRP gene bank  
5`- AGA CTG TAT GAA CAG AAC 
AGT GG-3` 
Smad7 antisense C Correspond to the region beginning with nucleotide number 1770 on 
mouse Smad7 gene bank  
5`-GGA CTC CAC GGC CTG AAG-3` 
 
 
 
 
Figure 3.10: Genotyping of transgenic offspring. To select CRP-Smad7 positive transgenic mice from negative ones, tail DNA from 4 weeks 
old offspring was analysed by PCR. Positive transgenic animals are indicated by a PCR product of 550 bp; abbreviations: F= female, M= male. 
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3.5 In vivo stimulation of Flag-Smad7 expression by LPS  
To prove the expression of Smad7 in the created transgenic animals analysis of protein lysates, tissue sections and RNA 
was performed by Western blots, immunohistochemical staining and RT-PCR after stimulation of the CRP promoter by 
i.p. LPS injections. 
3.5.1 Analysis of Flag-Smad7 expression by Western blotting 
In order to investigate the expression of Smad7 in transgenic mice Western blot analysis was done. To simplify the 
detection of transgenic derived Smad7 in protein lysates a Flag-tag was linked to Smad7 in the CRP-Smad7 plasmid. 
Detection of the Flag-tag by specific monoclonal antibodies in protein lysates from CRP-Smad7 transgenic mice was 
used to study the expression of transgenic derived Smad7 indirectly. As figure 3.11 shows CRP-Smad7 transgenic mice 
stimulated with LPS expressed Flag-Smad7. In comparison FVB, CD-1 wild type and S7?E1 (S7KO) mice do not 
express Flag-Smad7. Neither CCl4 nor LPS treatment alone induced expression of Flag-Smad7 in these mice strains. 
 
 
Figure 3.11:  Liver protein lysates (20 µg) from different strains as indicated were examined for expression of Flag (Flag-Smad7) by Western 
blot analysis. Representative photomicrographs of results obtained with 10 S7tg and 10 FVB wild type mice as well as 8 S7?E1 and 8 CD-1 
wild type mice after 8 weeks of CCl4, LPS and CCl4 + LPS intoxication are shown. For the detection of the Flag-tag monoclonal mouse anti-
Flag antibodies (SIGMA; F3165;20 µg/ml) and a Peroxidase-conjugated (HRP) polyclonal goat anti-mouse serum (Santa Cruz: sc-2005; 1:5000) 
were used. Blots were reprobed with monoclonal mouse anti-β-actin antibodies (SIGMA; A5441; 1:10000) to confirm equal protein loading. 
abbr.:S7tg = CRP-Smad7 transgenic mouse, FVB = wild type strain; S7?E1 = Smad7 knockout mouse, CD-1 = mixed wild type strain. 
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3.5.2 Analysis of Flag-Smad7 expression by immunohistochemical staining 
A further evidence for the expression of Flag-Smad7 in the transgenic animals created in this study provided 
immunohistochemical staining of tissue sections from CRP-Smad7 transgenic offspring after stimulation by i.p. 
injection of LPS. 4 µm thick sections from 3.5% formaldehyde (10% formalin) fixed tissues were stained with 
monoclonal antibodies against the Flag fragment. As expected transgenic mice stimulated by LPS or both CCl4 + LPS 
expressed Flag-Smad7 (figure 3.12).  
 
 
 
Figure 3.12: S7tg mice stimulated with both, LPS or CCl4 + LPS express the Flag fragment. Representative photomicrographs of mice liver 
sections from S7tg and FVB wild type treated for 8 weeks with CCl4 and/or LPS are shown. Untreated cells of both strains serve as controls. 
Brownish signals indicate Flag-Smad7 expression; Magnification x 100. 
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3.5.3 RT-PCR analysis to detect CRP-Smad7 RNA expression 
For RT-PCR analysis, RNA was isolated from liver tissues of transgenic offspring with “RNeasy Protect Mini Kit”. 2 µg 
of total RNA was used in order to amplify a potential Flag-Smad7-fragment of 550 bp using specific primers (see 
Material and Methods). To control the quality of the RNA used a CSRP2 gene fragment constitutively expressed in all 
the mouse genomes, was identified with two specifies primers. As figure 3.13 shows transgenic mice stimulated with 
LPS or both, CCl4 + LPS transcribed Flag-Smad7 specific RNA in contrast to wild type animals. 
 
 
Figure 3.13: Detection of Flag-Smad7-RNA. 2 µg of total RNA from mice was analysed by RT-PCR using a Omniscript RT Kit (50) 
(QIAGEN). Only LPS stimulated CRP-Smad7 transgenic mice expressed Flag-Smad7. The expression of CSRP2 RNA was analysed as a RNA 
quality control. 
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3.6 Induction of fibrotic liver damage in mice 
In order to investigate the antagonizing effect of Smad7 overexpression in hepatocytes during liver fibrogenesis, 
experimental mice were subjected to CCl4 induced fibrotic conditions.  
For this 78 experimental mice in the age of 4-8 months were chosen. CRP-Smad7 transgenic mice (S7tg), wild type 
mice with FVB background, Smad7 knockout animals and the corresponding wild type mice with CD-1 background 
were used for this study. The Smad7 knockout mouse strain carries a targeted deletion of exon1, including the start 
codon and parts of intron 1, within the Smad7 gene. These mice will be referred to herein as S7?E1 mice.  
The animals were divided into four groups. For induction of fibrosis the first group was administered 25% CCl4 in 
mineral oil interperitoneal (i.p.) two times per week. To induce the CRP promoter and cause Smad7 overproduction in 
hepatocytes of CRP-Smad7 transgenic mice the second group was treated with LPS (10 µg LPS in PBS/25 g mouse. The 
LPS dose was increased up to 25 µg/ mouse after six weeks.) i.p. only three times per week. In order to compare the 
effect of the Smad7 overproduction in hepatocytes of transgenic mice to FVB wild type animals under CCl4 fibrotic 
conditions, the third group was injected i.p. with both, CCl4 and LPS, two and three times per week, respectively. The 
fourth group of animals, consisting of mice with FVB and CD-1 backgrounds, was left untreated and served as a control. 
As an exception the control group of CCl4-treated animals was injected with mineral oil (50 µl/25 g body).  
The state of health of all experimental animals was controlled by determining their body weights every day. After 8 
weeks of stimulation and induction of experimental mice with LPS and/or CCl4 they were killed. The extent of liver 
damage could be determined preliminary by the observation of morphological changes of the liver (e.g. white pearls 
covering damaged livers of experimental mice). Further blood was taken for serum analysis; liver tissues were used for 
RT-PCR, Western blot and immunohistochemicla staining. Figure 3.14 gives an overview about the experimental setup. 
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Figure 3.14: Experimental setup for in vivo induction of fibrosis and stimulation of Smad7 expression in mice of different strains as indicated. 
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3.7 Smad7 expression in hepatocytes decreases collagen deposition in 
CCl4 treated mice 
A significant feature of chronic liver fibrosis is the deposition of abnormal matrix by up-regulation of matrix 
components including collagen. Collagen is one of main the components of the ECM produced by activated HSC in 
damaged tissues. Correspondingly, an effective method to reduce fibrosis could be the inhibition of collagen synthesis. 
Further increased collagen synthesis can serve as a marker of fibrosis.  
The collagen content measured by Picro Sirius red staining in all four animal groups (figure 3.15) proves that CCl4 
treatment induces liver damage. 10 FVB wild type mice (i.e. n = 10) synthesized 3.5 ± 0.4% collagen whereas S7tg mice 
(n = 10) produced 2.48 ± 0.2% collagen. That translates into a ratio of 1:1.4 (Table 3.2). Percentages give the size of 
stained areas compared to the total area investigated and are assumed to be proportional to the expression level of 
detected proteins. In the LPS treated group no noticeable difference between collagen expression in FVB wild type and 
S7tg mice can be detected. A significant difference in collagen synthesis between FVB wild type and S7tg can be 
observed in the CCl4 + LPS treated group. S7tg mice treated like this showed a reduced collagen synthesis (1.14 ± 
0.3%), whereas FVB wild type mice synthesize a relatively higher amount of collagen fibrils under the same fibrotic 
condition (3.84 ± 0.45%), (figure 3.15). That implies a 3.4 times higher collagen synthesis in FVB wild type than in 
S7tg mice. The quantitative data suggests a dramatic decrease of collagen fibrils by 70% in S7tg mice (n = 10) compared 
to wild type animals after induction of Smad7 expression. This finding is confirmed by Western blot analysis of protein 
lysates (figure 3.16). Treatment of the nitrocellulose membrane with polyclonal anti-collagen antibodies reveals a 
significant difference of collagen expression in S7tg mice compared to FVB wild type mice. This is visualized by 
different signal intensities in figure 3.16 lane 8 and 9. These results demonstrate that the decrease of collagen expression 
in CRP-Smad7 transgenic mice is due to Smad7 overexpression hepatocytes triggered by LPS co-administration. 
 
Table 3.2: Quantification of collagen in the liver of different mouse strains. The percentage gives the size of stained areas compared to the total 
area investigated. n=number of animals investigated, n. d.: not determined. For more information see legend of figure 3.15 and 3.17. 
 
Experimental mice Control (%) CCl4 (%) LPS (%) CCl4 + LPS (%) 
FVB (n = 10) 0.1 ± 0.01 3.5 ± 0.4 0.2 ± 0.03 3.84 ± 0.45 
S7tg (n = 10) 0.06 ± 0.02 2.48 ± 0.2 0.1 ± 0.01 1.14 ± 0.3 
CD-1 (n = 8) 0.08 ± 0.03 2.019 ± 0.4 n. d.  n. d. 
S7?E1 (n = 8) 0.09 ± 0.02 4.98 ± 0.2 n. d. n. d. 
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Figure 3.15: Smad7 overexpression leads to a 
reduction of the TGF-β signaling, displayed by a 
decrease of type I collagen synthesis in CCl4 
treated liver cells of mouse strains as indicated. 
(A) Representative photomicrographs of mice 
liver sections from S7tg mice and FVB wild type 
animals treated for 8 weeks with CCl4 and/or LPS 
are shown. Untreated cells served as controls. 
Sirius red staining was performed to measure 
collagen deposition; magnification x 100. (B) 
Morphometric quantification of 
immunohistochemical staining of type I collagen 
was carried out by selecting ten fields randomly 
from each section of different groups (8-10 
animals/group); LEICA QWIN software 
(Germany) was used. The graph shows the 
percentage of positive staining related to the total 
area investigated. 
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Figure 3.16: Protein lysates of different experimental mice were subjected to Western blot analysis for detection of collagen type I. Goat 
polyclonal anti-collagen type I antibodies (M-19, Santa Cruz Biotechnology, sc-8788, dilution 1:100) were used as first antibodies. Horseradish 
peroxidase linked anti–goat antibodies (Santa Cruz, sc-2033, donkey anti-goat Ig-HRP, dilution 1:2500) were used as second antibodies. 
Representative samples of differently treated FVB and S7tg derived liver tissues are shown as indicated. Blots were reprobed with anti-ß-actin 
antibodies to show equal loading. 
 
Comparison between S7?E1 mice and their correspondent CD-1 wild type animals (table 3.2) shows that S7?E1 mice 
produce 2.5 times more collagen fibrils than CD-1 wild type mice (figure 3.17). This result was confirmed by Western 
blot analysis (figure 3.18). After CCl4 treatment S7?E1 mice (n = 8) develop serious liver damage demonstrated by the 
synthesis of the highest amount of collagen (4.98 ± 0.2%) compared to all other strains tested. In sharp contrast S7tg 
mice (n = 10) synthesized 4.4 times less collagen when LPS was administered additionally. From these results it can be 
repeatedly concluded that Smad7 overexpression in hepatocytes of S7tg mice plays a pivotal role in the attenuation of 
collagen deposition in this mice strain.  
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Figure 3.17: Loss of Smad7 function leads to increased 
collagen type I synthesis in livers cells of CCl4 treated 
S7?E1 mice. (A) Representative photomicrographs of 
mice liver sections from CD-1 and S7?E1 strains treated 
for 8 weeks with CCl4 are shown. Untreated tissues of both 
strains serve as controls. Sirius red staining was performed 
to measure collagen deposition; magnification x 100. (B) 
Morphometric quantification of immunohistochemical 
staining. Ten fields were selected randomly from each 
section of different groups (6-8 animals/group) to quantify 
the Sirius red staining, LEICA QWIN software (Germany) 
was used. The graph shows the percentage of stained areas 
related to the total area investigated. 
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Figure 3.18: Loss of Smad7 by S7∆E1 mice causes enhanced expression of type I collagen compared to CD-1 wild type mice after CCl4 
dependent liver damage. Liver protein lysates (20 µg) were examined for type I collagen expression by Western blotting as indicated. 
Representative photomicrographs of results obtained with S7∆E1 and wild type mice after 8 weeks of CCl4 intoxication are shown. Blots were 
reprobed with monoclonal anti-β-actin antibodies to confirm equal protein loading. 
 
3.8 Expression of α-smooth muscle actin as a measure for activated 
hepatic stellate cells 
Pathologically activated HSCs are characterized by the expression of α-smooth muscle actin (α-SMA), the main 
component of the ECM and the cytoskeleton. Because the amount of α-SMA increases proportional to the part of 
injured liver, it is a useful marker to detect the fibrosis state of the liver. 
To ascertain the effect of transgenic derived Smad7 overexpression in hepatocytes on α-SMA synthesis in damaged 
liver, sections of experimental animals were analysed by immunohistochemical staining (figure 3.19 and 3.21). 
Immunostaining with monoclonal anti-α smooth muscle actin antibodies shows increased α-SMA synthesis being 
accompanied with increased liver damage in all CCl4 treated mice compared to untreated animals. S7∆E1 mice (n =8) 
exhibit the highest peak of α-SMA expression (figure 3.21). α-SMA expression varies from 3.9 ± 0.7% to 12.1 ± 1.1% 
synthesized by CD-1 and S7∆E1 strain mice and from 4.02 ± 1.3% to 8.0 ± 1.3% expressed by FVB and S7tg, 
respectively after CCl4 treatment (Table 3.3). There is no difference between α-SMA expression of FVB and S7tg mice 
in the LPS treated group (Figure 3.19). Apparently, LPS administration alone does not induce or inhibit any α-SMA 
expression. A significant difference in α-SMA expression appears after CCl4 + LPS treatment. S7tg mice show reduced 
α-SMA synthesis (1.4 ±  0.5% stained area) in comparison to FVB wild type exhibiting 9.7 ± 0.914% of stained area 
(figure 3.19). This corresponds to a 6.9 fold reduction. Another significant, 8.7-fold reduction of α-SMA expression 
show tissue sections of S7tg mice after CCl4 + LPS treatment compared to CCl4 treated S7∆E1 mice. CCl4 treated 
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S7∆E1 mice produce the highest amount of α-SMA, i.e. 12.1 ± 1.1% stained area in immunohistchemical stainings 
(Table 3.3).  
The comparison between α-SMA contents of liver tissues of FVB wild type, S7tg and S7∆E1 mice after treatment with 
CCl4 or CCl4 + LPS suggests that a reduction or elevation of α-SMA synthesis in transgenic mice can be attributed 
either to Smad7 overexpression or lack of Smad7 synthesis respectively..  
These results were confirmed by Western blot analysis of protein lysates of liver tisssues (figure 3.20, 3.22). Comparing 
bands after antibody treatment of nitrocellulose membranes reveals, that the amount of α-SMA in CCl4 + LPS treated 
S7tg mice is significantly reduced compared to equally treated FVB mice and CCl4 treated S7∆E1 mice. This reduction 
of α-SMA synthesis can be attributed to an inhibition of HSC activation, the main cause of α-SMA production, and is 
due to ectopic Smad7 overexpression. 
 
Table 3.3: Quantification of α-smooth muscle actin contents. Percentages give the size of stained areas compared to the total area investigated. 
n=number of animals investigated, n. d.: not determined. For more detail see legend of figures 3.19 and 3.21. 
 
Experimental mice Control (%) CCl4 (%) LPS (%) CCl4 + LPS (%) 
FVB (n = 10) 0.002 8.0 ± 1.3 0.003 ± 0.04 9.7 ± 0.914 
S7tg (n = 10) 0.001 4.02 ± 0.8 0.001 ± 0.05 1.4 ±  0.5 
CD-1 (n = 8) 0.003 3.9 ± 0.7 n. d. n. d. 
S7?E1 (n = 8) 0.002 12.1 ± 1.1 n. d.  n. d. 
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Figure 3.19: Smad7 overexpression leads to a reduction 
of TGF-β signaling and a decrease of α-SMA synthesis 
in liver cells of CCl4 treated S7tg mice. (A) 
Immunohistochemical staining of alpha smooth muscle 
actin (α-SMA) as a marker for activated HSCs. 
Representative photomicrographs of mice liver sections 
from S7tg and FVB wild type strains treated for 8 
weeks with CCl4 and/or LPS are shown. Untreated cells 
serve as controls; magnification x 100. (B) 
Morphometric quantification of immunohistochemical 
staining of α-SMA. Ten fields were selected randomly 
from each section of different groups (8-10 
animals/group); LEICA QWIN software (Germany) 
was used. The graph shows the percentage of stained 
areas related to the total area investigated. 
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Figure 3.20: Smad7 overexpression in S7tg mice decreases the expression of α-SMA compared to FVB wild type mice after CCl4 dependent 
liver damage. Liver protein lysates (20 µg) were examined for expression of α-SMA by Western blotting as indicated. Representative 
photomicrographs of results obtained with 10 S7tg and FVB wild type mice after 8 weeks of CCl4 intoxication. Blots were reprobed with a 
monoclonal anti-β-actin antibodies to confirm equal protein loading. 
(A)                                                                            (B) 
Figure 3.21: Loss of Smad7 function leads to increased α-SMA synthesis in liver cells of CCl4 treated S7?E1 mice. (A) Immunohistochemical 
staining of alpha smooth muscle actin (α-SMA) as a marker for activated HSCs. Representative photomicrographs of mice liver sections from 
CD-1 and S7?E1 strains treated for 8 weeks with CCl4.are shown. Untreated cells of both strains are controls; magnification x 100 (B) 
Morphometric quantification of immunohistochemical stainings. Ten fields were selected randomly from each section of different animal groups 
(3-8 animals/group) for quantification of α-SMA staining, LEICA QWIN software (Germany) was used. The graph shows the percentage of 
stained areas related to the total area investigated. 
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Figure 3.22: Loss of Smad7 in S7∆E1 mice causes enhanced expression of α-SMA compared to CD-1 wild type mice after CCl4 dependent 
liver damage. Liver protein lysates (20 µg) were examined for expression of α-SMA by Western blotting as indicated. Representative 
photomicrographs of results obtained with S7∆E1 and wild type mice after 8 weeks of CCl4 intoxication are shown. Blots were reprobed with a 
monoclonal anti-β-actin antibodies to confirm equal protein loading. 
 
3.9 Smad7 overexpression in hepatocytes reduces levels of hyaluronic 
acid in CCl4 treated mice 
Increased amounts of hyaluronic acid (HA) in the serum of experimental animals provide indirect evidence for the 
extent of liver damage and fibrosis. HA is a polymer composed of repeating dimeric units of glucuronic acid and N-
acetyl-glucosamine. It forms the core of complex proteoglycan aggregates found in the extracellular matrix (ECM).  
Analysis of hyaluronic acid concentrations was carried out using the “Hyaluronic Acid Test Kit, CORGENIX after 8 
weeks of induction of liver damage by i.p. CCl4 injections or combined CCl4 + LPS treatment. For this purpose serum of 
experimental mice was examined, which was obtained from 1 ml blood by a needle prick in the eye of anaesthetized 
animals. 
Immunohistochemical staining of liver sections suggests that CCl4 treated CD-1, FVB and S7tg mice have 
approximately the same concentration of HA in the serum (355 ± 22.5, 392.2 ± 21 and 411 ± 31 µg/ml respectively) 
(Table 3.4, figure 3.23). CCL4 treated S7?E1 mice instead exhibit an increased concentration of HA (562.2 ± 30.2 
µg/ml). LPS treated animals produce as little HA as the control group presenting no fibrotic state. A remarkable 
difference in HA concentrations measured appears in the group of CCl4 + LPS treated animals. S7tg mice show a 
reduced level of HA synthesis of 200.5 ± 18.8 µg/ml, in comparison to FVB mice with an increased level of HA 
synthesis of 440.06 ± 44.081 ng/ml. This implies a more than twofold reduction of HA synthesis. From these results it 
can be concluded that Smad7 overexpression in hepatocytes triggered by LPS co-administration under CCL4 induced 
fibrotic conditions leads to a significant reduction of HA synthesis in S7tg mice. 
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Figure 3.23: Analysis of the concentrations of hyaluronic acid in the serum of mice was carried out using the Hyaluronic Acid Test Kit from 
CORGENIX. Samples were taken after 8 weeks of treatment with CCl4 and/or LPS as indicated. Untreated mice served as controls. (A) Smad7 
overexpression decreases the sensitivity for liver damage and fibrogenesis after CCl4 intoxication in S7tg mice. (B) Loss of Smad7 leads to 
enhanced TGF-β signaling and increased concentrations of hyaluronic acid in the serum of S7?E1 mice compared to CD-1 wild type animals 
after CCl4 intoxication.  
 
Table 3.4: Effect of Smad7 overexpression on hyaluronic acid levels in the serum of mice as indicated (µg/ml). n=number of animals 
investigated, n. d.: not determined.  
 
Experimental mice Control  CCl4 LPS  CCl4 + LPS  
FVB (n = 10) 89 ± 10.8 392.2 ± 21 146 ± 23.5 440 ± 44 
S7tg (n = 10) 84 ± 9.2 411 ±  31 138 ± 14 200.5 ± 18.8 
CD-1 (n = 8) 86 ± 7.5 355 ± 22.5 n. d. n. d. 
S7?E1 (n = 8) 91± 8.6 562 ± 30.2 n. d. n. d. 
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3.10 Smad7 overexpression in hepatocytes reduces the level of 
hydroxyproline in CCl4 treated mice 
Because hydroxyproline (HP) is the main component of collagen, HP levels in liver tissues provide indirect information 
about the level of collagen synthesis and the fibrotic state of liver cells. 
In order to determine the HP concentration in the serum of experimental mice a HP assay was carried out (2.11). 
Approximately 0.5 g liver tissue from the right and left liver lobes was analysed. The data obtained indicates that CCl4 
induced liver damage causes increased HP synthesis in all experimental mice. S7?E1 strain mice (n = 8) show the 
highest HP concentration (463.3 ± 19.8 µg/g liver), (Table 3.5 and figure 3.24). No significant difference of HP levels 
between FVB wild type mice (n = 10) and S7tg mice (n = 10) could be determined (figure 3.24). A significant reduction 
of HP synthesis can be seen in S7tg mice after CCl4 + LPS treatment (129.4 ± 19.2 µg/g liver) (figure 3.24). In 
comparison the HP concentration of FVB wild type animals was 331.7 ± 27.1 µg/g liver under the same fibrotic 
conditions. This effect can be explained as a result of ectopic Smad7 overexpression triggered by simultaneous LPS 
injection.  
In summary, it can be concluded that S7tg mice exhibit a 50% reduced HP concentration caused by ectopic Smad7 
overexpression in hepatocytes (table 3.5, figure 3.24A). The absence of Smad7 in S7?E1 mice in contrast leads to an 
elevated HP level (Table 3.5, figure 3.24B). 
 
Table 3.5: Effect of Smad7 overexpression on serum concentrations of Hydroxyproline in mice (µg/g liver). n=number of animals investigated, 
n. d.: not determined.  
 
Experimental mice Control  CCl4  LPS  CCl4 + LPS  
FVB (n = 10) 67 ± 9 306.6± 26 102 ± 10 331.7 ± 27 
S7tg (n = 10) 60 ± 7.2 276.3 ± 16 101 ± 10 129.4 ± 19 
CD-1 (n = 8) 64 ± 4.5 274.3 ± 12 n. d. n. d. 
S7?E1 (n = 8) 70 ± 3.6 463.3 ± 20 n. d. n. d. 
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         (A)                                                                                                                        (B) 
 
Figure 3.24: Spectrophotometrical analysis (Pharmacia Biotech, Ultraspec 2000; wavelength of 558 nm) of hydroxyproline concentrations was 
carried out as a measure for the degree of fibrosis in liver tissue samples after 8 weeks treatment with CCl4 and/or LPS as indicated. (A) Smad7 
overexpression decreases the sensitivity for liver damage and fibrogenesis after CCl4 intoxication. Serum analysis of S7tg and FVB mice were 
compared. (B) Loss of Smad7 leads to an enhanced TGF-β signaling and an increased level of hydroxyproline after CCl4 intoxication. Serum 
concentrations of S7?E1 and CD-1 mice were analysed. 
 
3.11 Smad7 overexpression desensitizes hepatocytes for TGF-β/Smad 
signaling 
Smad7 is known to antagonize the TGF-β signal pathway. Binding of Smad7 to the TGF-β type I receptor (TβRI) 
hinders its subsequent phosphorylation by the TGF-β type II receptor (TβRII). An important measure of function of the 
TGF-β/Smad signal pathway is the relative presence or absence of Phospho-Smad2 in cell nucleus. 
In order to substantiate the effect of Smad7 overexpression in hepatocytes, immunohistological staining of Phospho-
Smad2 in liver sections of differently treated mice was carried out as described in 2.9.5. 
After treatment with CCl4 an intensified staining of the nucleus in liver sections can be observed in all mouse groups 
(figure 3.25 and 3.27). Quantification reveals that FVB (n = 10), S7tg (n = 10) and CD-1 (n = 8) mice exhibit a similar 
level of nucleus staining i.e. 78.5 ± 4.8%, 78.3 ± 4.7% and 74.8 ± 7.2% respectively, whereas liver sections of S7?E1 
(n = 8) show the highest level of staining (92.5 ± 4.2%), (figure 3.25 and 3.27). There is no significant difference of 
Phospho-Smad2 expression in different mice strains after LPS treatment. A significant difference in Phospho-Smad2 
staining in the nuclei can be observed in the CCl4 + LPS treated group. As shown in table 3.6 and figure 3.25, co-
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injection of CCl4 + LPS result in a threefold reduction of nucleus staining of liver cells of S7tg mice (26.6 ± 5.6%) 
compared to cells of FVB wild type animals (77.4 ± 7%) under the same fibrotic conditions. The significant reduction of 
nucleus staining of S7tg cells can be explained as an effect of transgenic derived Smad7 overexpression, which is 
triggered by LPS administration.  
The immunohistochemical results are in line with Western blot analysis of Phospho-Smad2 in liver cell lysates. Lysates 
of S7tg mice show weaker bands for Phospho-Smad2 than lysates of FVB wild type and S7?E1 mice (figure 3.26 and 
3.28).  
In summary one can conclude that Smad7 overexpression in hepatocytes interrupts the TGF-β signal pathway by 
blocking R-Smad (Smad2/3) phosphorylation and thus their subsequent translocation into the nucleus of hepatocytes. 
Western Blot analysis and immunohistochemical staining gave evidence for that scenario by showing that under the 
same CCl4 induced fibrotic conditions S7tg mice exhibit drastically reduced fibrotic characteristics and less Phospho-
Smad2 signaling in comparison to S7?E1 mice and FVB wild type animals. 
 
Table 3.6: Effect of Smad7 overexpression on the level of Phospho-Smad2 in cell nuclei (%).The percentage gives the size of stained areas 
compared to the total area investigated. n=number of animals investigated, n. d.: not determined. For more information see legend of figure 3.25 
and 3.27. 
 
Experimental mice Control  CCl4  LPS  CCl4 + LPS  
FVB (n = 10) 0.3 78.5 ± 4.9 8.5 ± 2.8 77.4 ± 7.1 
S7tg (n = 10) 0.1 78.3 ± 4.8 5.4 ± 2.4 26.6 ± 5.6 
CD-1 (n = 8) 0.2 74.9 ± 7.2 n. d. n. d. 
S7?E1 (n = 8) 0.4 92.5 ± 4.2 n. d. n. d. 
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Figure 3.25: Smad7 overexpression leads to a blockade of 
TGF-β signaling and a decreased level of Phospho-Smad2 
in the nucleus (A) Representative photomicrographs of 
mice liver sections from S7tg and FVB mice treated for 8 
weeks with CCl4 and/or LPS are shown. Untreated animals 
serve as controls. Phospho-Smad2 immunohistochemical 
staining was performed as a quantitative measurement for 
TGF-β signaling; arrows indicate positive signals; 
magnification x 200. (B) Morphometric quantification of 
immunohistochemical staining. Ten fields were selected 
randomly from each section of different groups (8-10 
animals/group); LEICA QWIN software (Germany) was 
used. The graph shows the percentage of nuclear staining 
related to the total area investigated; about 200 cells were 
evaluated per field observation. 
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Figure 3.26: Smad7 overexpression leads to reduced levels of Phospho-Smad2 compared to FVB wild type mice after CCl4 dependent liver 
damage. Liver protein lysates (20 µg) were examined for Phospho-Smad2 by Western blot analysis as indicated. Representative 
photomicrographs of results obtained with lysates of 10 S7tg and FVB wild type mice after 8 weeks of CCl4 intoxication and LPS treatment as 
indicated are shown. Blots were reprobed with a monoclonal anti-β-actin antibodies to confirm equal protein loading. 
 
 (A)                                                                             (B) 
 
 
For description of figure 3.37 see next page. 
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Figure 3.27: Loss of Smad7 function leads to enhanced TGF-β signaling and increased amount of Phospho-Smad2 in the nucleus after CCl4 
intoxication. S7?E1 and CD-1 wild type mice were compared. (A) Representative photomicrographs of mice liver sections from CD-1 wild 
type and S7?E1 mice treated for 8 weeks with CCl4 are shown; untreated animals serve as controls. Phospho-Smad2 immunohistochemical 
staining as a quantitative measurement for TGF-β signaling was performed; brown staining indicates positive signals; magnification x 200. (B) 
Morphometric quantification of immunohistochemical staining. Ten fields were selected randomly from each section of different groups (3-8 
animals/group) for Phospho-Smad2 staining, LEICA QWIN software (Germany) was used. The graph shows the percentage of nuclear staining 
related to the total area investigated. About 200 cells were evaluated per observation field, stained cells were counted and expressed as 
percentage of total cells investigated. 
 
 
Figure 3.28: Loss of Smad7 in S7∆E1 mice causes enhanced Smad2 phosphorylation compared to CD-1 wild type mice after CCl4 dependent 
liver damage. Liver protein lysates (20 µg) were examined for Phospho-Smad2 by Western blot analysis as indicated. Representative 
photomicrographs of results obtained with S7∆E1 and wild type mice after 8 weeks of CCl4 intoxication are shown. Blots were reprobed with a 
monoclonal anti-β-actin antibody to confirm equal protein loading. 
 
Direct determination of Smad7 expression in liver tissues of experimental mice by immunohistochemical staining and 
Western blotting analysis confirms the conclusion that the interruption of TGF-β/Smad signaling is due to the 
stimulation of transgenic derived Smad7 overexpression in hepatocytes. Both methods demonstrate the excess of ectopic 
Smad7 production in transgenic mice, compared to basal Smad7 expression of wild type animals (figures 3.29 and 3.30). 
Quantification of Smad7 immunostaining indicates (figure 3.29) an invert proportion between overexpression of Smad7 
and the extent of liver damage (Table 3.7). In liver tissue sections of different mouse strains Smad7 signals appear 
predominantly in undamaged regions. Western blot analysis confirms the result with exception of relative high Smad7 
expression in CD-1 mice (figure 3.30-31). Because FVB wild type and S7?E1 mice have developed much more fibrotic 
tissues than S7tg under the same fibrotic condition, the reduction of liver damage in CRP-Smad7 transgenic mice can be 
interpreted as an evidence for blocking of the TGF-β signal pathway. 
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Table 3.7: Quantification of immunohistochemical staining of Smad7 in liver sections (%).The percentage gives the size of stained areas 
compared to the total area investigated. n=number of animals investigated, n. d.: not determined. For more information see legend of figure 3.29 
and 3.31. 
 
Experimental mice Control  CCl4  LPS  CCl4 + LPS  
FVB (n = 10) 0.13 1.25 ±  0.5 0.75 ± 0.5 2.4 ± 0.7 
S7tg (n = 10) 0.12 4.6 ± 1.1 5.9 ± 1.1 7.4 ± 0.7 
CD-1 (n = 8) 0.15 4.5 ± 1.1 n. d.  n. d. 
S7?E1 (n = 8) 0 0 ± 0 n. d. n. d. 
 
(A) 
 
 
 
 
 
 
 
 
(B) 
 
Figure 3.29 Smad7 overexpression in CRP-Smad7 
transgenic mice is induced by LPS administration. (A) 
Smad7 immunostaining was used as a quantitative 
measurement for blockade of TGF-β activity and the 
effect of LPS. Representative photomicrographs of mice 
liver sections from S7tg and FVB mice treated for 8 
weeks with both CCl4 and LPS are shown. Untreated cells 
serve as controls. Arrows indicate positive signals; 
magnification x 200. (B) Morphometric quantification of 
immunohistochemical staining of Smad7. Ten fields were 
selected randomly from each section of different groups 
(8-10 animals/group); LEICA QWIN software (Germany) 
was used. The graph shows the percentage of stained area 
related to the total area investigated. About 200 cells were 
evaluated per observation field. Stained cells were 
counted and expressed as percentage of total cells 
investigated. 
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Figure 3.30: Transgenic derived Smad7 is overexpressed after LPS administration in S7tg mice compared to FVB wild type mice. Liver protein 
lysates (20 µg) of mouse strains as indicated were examined for Smad7 expression by Western blot analysis. Representative photomicrographs 
of results obtained with 10 S7tg and FVB wild type mice after 8 weeks of treatment as indicated are shown. Blots were reprobed with a 
monoclonal anti-β-actin antibodies to confirm equal protein loading. 
  
(A)           (B) 
 
 
 
For description of figure 3.31 see next page. 
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Figure 3.31: TGF-β activity causes Smad7 synthesis as a negative feedback regulation in CD-1 wild type mice but not in S7?E1 mice. (A) 
Immunohistochemical staining of Smad7. Representative photomicrographs of mice liver sections from S7?E1 and CD-1 wild type mice 
treated or not (control) for 8 weeks with CCl4 are shown; arrows indicate positive signals; magnification x 200. (B) Morphometric quantification 
of immunohistochemical staining of Smad7 as a measurement for negative feedback regulation of TGF-β activity in CD-1 wild type and S7?E1 
mice treated with CCl4. Ten fields were selected randomly from each section of different animal groups (3-8 animals/group); LEICA QWIN 
software (Germany) was used. The graph shows the percentage of stained areas related to the total area investigated. About 200 cells were 
evaluated per observation field. Stained cells were counted and expressed as percentage of total cells investigated.  
Smad7 overexpression does not affect Smad2 and Smad3 synthesis 
To investigate the effect of Smad7 overexpression in hepatocytes on the level of endogenous derived Smad2 and Smad3, 
immunohistochemical staining and Western blot analysis was carried out. Immunohistochemical staining points to a 
constant expression of Smad2 and Smad3 distributed evenly in the cell cytoplasm of S7tg, FVB as well as S7?E1 mice 
and CD-1 mice (figure 3.32 and 3.35). These results suggest that Smad7 overexpression in hepatocytes has no effect on 
endogenous Smad2 and Smad3 expression which could be confirmed by Western blot analysis of protein lysates of 
experimental animals (figure 3.33 and 3.34). Both proteins could be detected in similar amounts in all lysates. 
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Figure 3.32: Representative photomicrographs of mice 
liver sections from mouse strains as indicated after 
treatment with CCl4 and/or LPS. Untreated cells serve as 
controls. Immunohistochemical staining of Smad2 was 
performed; the arrows indicate positive signals; 
magnification x 200. 
 (A) Smad7overexpression does not affect constitutive 
expression of Smad2 in S7tg mice. (B) Loss of Smad7 
does not affect constitutive expression of Smad2 by S7∆E1 
mice when compared to CD-1 wild type mice after CCl4 
dependent liver damage. 
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Figure 3.33: Smad7 overexpression or loss of Smad7 does not affect constitutive expression of Smad2. Liver protein lysates (20 µg) of treated 
mouse strains as indicated were examined for Smad2 expression by Western blot analysis. Representative photomicrographs of results obtained 
after 8 weeks of CCl4 and LPS intoxication are shown. Blots were reprobed with a monoclonal anti-β-actin antibodies to confirm equal protein 
loading. 
 
 
 
Figure 3.34: Smad7 overexpression or loss of Smad7 does not affect constitutive expression of Smad3. Liver protein lysates (20 µg) of 
differently treated mouse strains as indicated were examined for Smad3 expression by Western blots analysis. Representative photomicrographs 
of results are shown. Blots were reprobed with a monoclonal anti-β-actin antibodies to confirm equal protein loading. 
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Figure 3.35: Immunohistochemical staining 
of Smad 3 in liver tissue sectionsa of 
different mouse strains after CCl4 and/or LPS 
treatment as indicated. Representative 
photomicrographs are shown. Arrows 
indicate Smd3 positive signals; magnification 
x 200. (A) Smad7 overexpression does not 
affect constitutive expression of Smad3 by 
S7tg compared to FVB wild types mice after 
CCl4 dependent liver damage. (B) Loss of 
Smad7 does not affect constitutive expression 
of Smad3.  
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3.12 Smad7 overexpression in hepatocytes decrease the serum levels of 
liver enzymes in CCl4 treated mice 
Analysis of serum levels of liver enzymes reveals important parameters of the state of liver fibrosis. For example 
aspartate aminotransferase (AST) present in hepatocytes and myocytes catalyses the reversible transfer of an amino 
group from L-glutamic acid to oxaloacetic acid, forming alpha-oxoglutaric acid and L-aspartic acid. Its concentration 
raises proportional to the damage of inner organs e.g. due to liver fibrosis and heart myocardial infraction. Following a 
damage of those cells, AST is released into the blood. Measuring the concentration of AST in the serum can thus give 
important information about the state of organ damage. 
Alanin aminotransferase (ALT) found primarily in the liver, is also released into the bloodstream as a result of liver 
damage. Its increased level in the serum is a marker of liver fibrosis. Further alkaline phosphatase (AP) a liver enzyme 
which splits phosphate groups from nucleotides and proteins shows increased serum concentrations at liver fibrosis. To 
measure concentrations of AST, ALT and AP serum was prepared from 1 ml blood by needle prick into the eyes of 
anesthetized experimental mice.  
Analysis showed that AST, ALT and AP levels increase rapidly with CCl4 induced liver damage in experimental mice. 
Serum analysis in this study reveals that AST concentration of CCl4 treated S7tg mice (n = 10) is 132.9 ± 18.9 U/L. This 
is slightly reduced in comparison to AST levels in equally treated FVB wild type animals (n = 10) (167.6 ± 13.6 U/L) 
(figure 3.36). CD-1 mice (n = 8) release approximately the same amount of AST (121.3 ± 18.8 U/L) as S7tg mice but 
only half as much as S7∆E1 strain mice (n = 8) (Table 3.8 and figure 3.37). No remarkable difference between AST 
levels in the serum of FVB and S7tg mice could be measured in LPS treated group. A significant reduction of the AST 
level in the serum of S7tg mice can be observed in the CCl4 + LPS treated group. After this medication FVB wild type 
mice produced approximately threefold more serum AST (i.e. 151.5 ± 6.7 U/L) than S7tg mice (figure 3.36). A 
comparison between CCl4 treated S7∆E1 mice and S7tg mice after CCl4 + LPS treatment demonstrates that S7tg mice 
exhibit heavily reduced AST serum concentrations. Although both groups are treated differently this result proves that 
transgenic Smad7 overexpression in hepatocytes triggers a strong reduction of AST in the serum of experimental mice. 
That effect can be correlated to a lower state of liver damage due to Smad7. 
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Table 3.8: Serum concentrations of liver enzymes in experimental miceas indicated. For comparison the data of hyaluronic acid are showed 
repeatedly. See figure 3.23 and Table 3.4.  n=number of animals investigated.  
 
Experimental mice treatment AST (U/L) ALT (U/L) AP (U/L) Hyaluronic acid (µg/ml) 
FVB (n = 10) CCl4 167.6 ± 13.6 428.8 ± 23.6 198.4 ± 15. 392.2 ± 21 
S7tg (n = 10) CCl4 132.9 ± 18.9 413.1 ± 24.7 191.4 ± 11.8 411 ± 31 
CD-1(n = 8) CCl4 121.3 ± 16.8 362.7 ± 15.4 191.3 ± 13.3 355 ± 22.5 
S7?E1 (n = 8) CCl4 262.3 ± 16.6 605.5 ±  22.3 247.3 ± 9.8 562 ± 30.2 
FVB (n = 10) LPS 25.13 ±  6.7 91.12 ± 9.5 108.25 ± 20.9 146 ± 23.5 
S7tg (n = 10) LPS 28.4 ± 4.2 87.9 ±  11.8 81.5 ± 11.2 138 ± 14 
FVB (n = 10) CCl4 + LPS 151.5 ± 6.7 307.4 ±  27.7 190.6 ± 8.4 440 ± 44 
S7tg (n = 10) CCl4 + LPS 50.4 ± 12.6 151.1 ± 26.1 134.9 ± 14.9 200.5 ± 18.8 
FVB (n = 8) without 24.04 ± 9.01 54.5 ±  4.3 64.5 ± 9.7 89 ± 10.8 
 
                                                                                                                                                                                                                                                              
 
                Figure 3.36                                                                                                     Figure 3.37 
 
Figure 3.36: Smad7 overexpression decreases serum levels of AST i.e. the sensitivity for liver damage and fibrogenesis after CCl4 intoxication. 
S7tg mice were compared to FVB wild type animals. Evaluation of asparate aminotransferase (AST) concentrations in the serum was measured 
after 8 weeks of treatment as indicated at 670 nm with VITROS Chemistry Products; n = number of animals investigated in triplicate 
measurements. S7tg mice exhibit significantly more AST in the serum than FVB mice after CCL4 + LPS treatment. This can be correlated to a 
lower state of liver damage. 
 
Figure 3.37: Loss of Smad7 increases serum levels of AST i.e. the sensitivity for liver damage and fibrogenesis after CCl4 intoxication. S7∆E1 
mice were compared to CD-1 wild type animals. Asparate aminotransferase (AST) serum concentration was measured at 670 nm with VITROS 
Chemistry Products after 8 weeks of CCl4 treatment; n = number of animals investigated in triplicate measurements. 
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In line with AST levels indicating increased liver damage as a result of CCl4 induced fibrosis, ALT concentrations are 
elevated after CCl4 treatment in all mouse strains tested. Nevertheless, in early stages of liver damage the AST 
concentration is approximately half of that of ALT. The inverse scenario only occurs in the case of cirrhosis.  
Measurement of ALT concentrations in the sera shows only slight differences between FVB (n = 10) (428.8 ± 23.6 
U/L), CD-1 (n = 8) (362.7 ± 15.4 U/L) and S7tg mice (n = 109) (413.1 ± 24.7 U/L) under CCl4 induced fibrotic 
conditions (Table 3.9 and figure 3.38 and 3.39). This difference increases significantly if experimental mice were 
exposed to additional LPS co-injunction. Figure 3.38 shows that in S7tg mice then only ALT concentrations of 151.1 ± 
26.2 U/L could be detected. In comparison FVB mice produced a twofold higher serum concentration of ALT (307.4 ± 
27.7 U/L). A comparison between ALT serum concentrations of S7∆E1 mice and S7tg mice reveals that S7∆E1 animals 
synthesize the highest amount of serum ALT i.e. 605.5 ± 22.3 U/L. This amount is fourfold higher than the one 
measured in S7tg mice (figure 3.38-3.39). 
 
Table 3.9: Effect of Smad7 overexpression on ALT serum concentrations (U/L). n=number of animals investigated, n. d.: not determined.  
 
Experimental mice Control  CCl4  LPS  CCl4 + LPS  
FVB (n = 10) 54.5 ± 4.3 428.8 ± 23.6 91.12 ± 9.5 307.4 ± 27.7 
S7tg (n = 10) 50.3  ± 3.3 413.1 ± 24.7 87.9 ± 11.8 151.1 ± 26.1 
CD-1 (n = 8) 48.2 ± 2.4 362.7 ± 15.4 n. d. n. d. 
S7?E1 (n = 8) 55.2 ± 3.6 605.5 ± 22.3 n. d. n. d. 
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Figure 3.38: Smad7 overexpression decreases serum 
levels of ALT i.e. reduces the sensitivity for liver 
damage and fibrogenesis after CCl4 intoxication. S7tg 
mice were compared to FVB wild type animals after 
different treatsments as indicated. Alanine 
aminotransferase (ALT) concentrations in the serum 
were measured at 340 nm with VITROS Chemistry 
Products; n, number of animals investigated in triplicate 
measurements. 
 
 
 
 
 
 
 
 
 
 
Figure 3.39: Loss of Smad7 increases the serum level 
of ALT i.e. enhances the sensitivity for liver damage 
and fibrogenesis after CCl4 intoxication. S7∆E1 mice 
were compared to CD-1 wild type animals after 8 
weeks of CCl4 treatment. Serum concentrations of 
alanine aminotransferase (ALT) were measured at 340 
nm with VITROS Chemistry Products; n = number of 
animals investigated in triplicate measurements. 
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As expected based on the results of AST and ALT measurements, alkaline phosphatase (AP) serum levels do not show 
significant differences between FVB, S7tg and CD-1 mice after CCl4 treatment. Again in the serum of S7∆E1 mice (n = 
8) the highest concentration of the fibrosis marker enzyme was detected. AP levels were measured to be 247.3 ± 9.8 U/L 
(Table 3.10, figure 3.40 and 3.41). LPS treatment and the resulting Smad7 overexpression causes the reduction of AP 
levels in S7tg mice to 81.5 ± 11.2 (U/L). In comparison, FVB mice produce up to 108.25 ± 20.9 U/L serum after the 
same treatment. A reduction of AP levels (134.9 ± 14.9 U/L) is observed in the serum of S7tg mice after CCl4 + LPS 
treatment in comparison to CCl4 treated mice. In contrast FVB mice showed AP levels of 190.6 ± 8.4 U/L (figure 3.40). 
 
Table 3.10: Effect of Smad7 overexpression on serum concentrations of alkaline phosphatase (U/L). n=number of animals investigated, n. d.: 
not determined.  
 
Experimental mice Control  CCl4 LPS  CCl4 + LPS  
FVB (n = 10) 64.5 ± 9.7 198.4 ± 15.7 108.25 ± 20.9 190.6 ± 8.4 
S7tg (n = 10) 60.3 ± 2.3 191.4 ± 11.8 81.5 ± 11.2 134.9 ± 14.9 
CD-1 (n = 8) 58.2 ± 4.3 191.3 ± 13.3 n. d. n. d. 
S7?E1 (n = 8) 65 ± 4.5 247.3 ± 9.8 n. d. n. d. 
 
 
 
                  Figure 3.40                                                                                                   Figure 3.41 
For description of figures 3.40 and 3.41 see next page.  
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Figure 3.40: Smad7 overexpression decreases the serum level of AP i.e. decreases the sensitivity for liver damage and fibrogenesis. S7tg mice 
were compared to FVB wild type animals after different intoxication treatments as indicated. Alkaline phosphatase serum concentrations were 
measured at 400 nm with VITROS Chemistry Products; n, number of animals investigated in triplicate measurements. 
 
Figure 3.41: Loss of Smad7 increases serum concentrations of AP i.e. increases sensitivity for liver damage and fibrogenesis after CCl4 
intoxication. S7∆E1 mice were compared to CD-1 wild type animals after CCl4 treatment. Evaluation of Alkaline phosphatase in the serum was 
measured at 400 nm with VITROS Chemistry Products; n, number of animals investigated in triplicate measurements. 
 
In summary the measurements of AST, ALT and AP serum concentrations in differently treated mice reveals that 
Smad7 expression reduces the amount of fibrosis marker enzymes in the serum. Thus it can be interpreted, that Smad7 
overexpression in hepatocytes can reduce liver damage in CCl4 exposed animal. 
 
3.13 Smad7 overexpression reduces apoptosis of liver cells in CCl4 
treated mice 
Apoptosis is applied to a group of characteristic structural and molecular events that separate this type of cell deletion 
from necrosis. In contrast to necrosis which involves death of a group of cells simultaneously, apoptosis can occur in a 
single cell surrounded by a group of viable cells. There is a distinct and precisely localized control over the fate of 
specific cells in a mixed cell population that undergo apoptosis. Diverse groups of specific molecules are involved in the 
apoptosis pathway. One set of mediators implicated in apoptosis belong to the asparate-specific cysteinyl proteases or 
caspases. A member of this family, caspase-3 (CPP32, apopain, YAMA) has been identified as being a key mediator of 
apoptosis of mammalian cells. Determining the amount of caspase-3 in a cell gives indirect evidence whether it is 
apoptotic. 
In order to determine the effect of Smad7 overexpression on apoptosis immunostaining analysis was carried out using 
anti-caspase-3 antibodies. The result obtained suggests that CCl4 induced fibrosis causes an increasing number of 
apoptotic cells in fibrotic regions of the liver. In contrast non-fibrotic liver regions were not affected by apoptosis. Based 
on the effects of Smad7 overexpression described earlier in this thesis less apoptotic cells were expected in tissue 
sections of S7tg mice compared to wild type animals. Quantitative analysis of anti-caspase-3 immunohistochemical 
staining based on direct cell counting under a light microscope (figure 3.42 and 3.43) confirms that expectation. In 
sections of CCl4 treated animals equally low anti-caspase-3 stainings could be detected i.e. 3 ± 0.9%, 2.3 ± 0.7% and 
2.12 ± 0.8% in cells of FVB (n = 10), S7tg (n = 10) and CD-1 (n = 8) mice respectively (Table 3.11). In contrast liver 
sections of S7?E1 mice showed a higher amount of apoptotic caspase-3 signals. Additional treatment with LPS causes 
a drastic reduction of anti-caspase-3 signals in cells of S7tg mice to 0.6%. In comparison FVB wild type cells exhibit an 
apoptotic signal rate of 2.8 ± 0.8% under similar CCl4 fibrotic condition with LPS co-administration. That implies a 4.8-
fold reduction of apoptosis in S7tg mice, most probably as a result of Smad7 overexpression in hepatocytes. 
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Table 3.11: Effect of Smad7 overexpression on apoptosis. Anti-caspase-3 immunohistochemical staining of liver sections of mouse strains as 
indicated was quantified. n=number of animals investigated, n. d.: not determined. Percentages give the amount of stained areas in relation to the 
total area investigated. For more information see legend of figures 3.42 and 3.43. 
 
Experimental mice Control (%) CCl4 (%) LPS (%)  CCl4 + LPS (%) 
FVB (n = 10) 0.25 3 ± 0.92 0.5 ± 0.5 2.8 ± 0.8 
S7tg (n = 10)  0.2 2.3 ± 0.7 0.5 ± 0.5 0.6 ± 0.7 
CD-1 (n = 8) 0.3 2.1 ± 0.8 n. d. n. d. 
S7?E1 (n = 8) 0.3 5 ± 0.5 n. d. n. d. 
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Figure 3.42: Smad7 overexpression leads to a blockade 
of TGF-β signaling and a reduction of hepatocyte 
apoptosis in mice. S7tg mice were compared to FVB wild 
type animals. (A) Immunohistochemical staining of 
cleaved caspase 3 was performed to identify apoptotic 
cells. Representative photomicrographs of mice liver 
sections treated for 8 weeks as indicated are shown. 
Untreated cells serve as controls. Arrows indicate positive 
signals; magnification x 200. (B) Morphometric 
quantification of immunohistochemical stainings depicted 
in A. Ten fields were selected randomly from each section 
of different groups (8-10 animals/group); LEICA QWIN 
software (Germany) was used. The graph shows the 
percentage of stained areas related to the total area 
investigated; about 200 cells were evaluated per 
observation field, stained cells were counted and 
expressed as percentage of total cells investigated. 
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Figure 3.43: Loss of Smad7 leads to an 
intensification of TGF-β signaling and an increase 
of hepatocyte apoptosis. S7∆E1 mice were 
compared to CD-1 wild type animals. (A) 
Immunohistochemical staining of cleaved caspase 
3 was performed to identify apoptotic cells. 
Representative photomicrographs of mice liver 
sections from S7∆E1 and CD-1 mice as indicated 
are shown; untreated cells serve as controls; 
Brown staining indicates positive signals; 
magnification x 200. (B) Morphometric 
quantification of immunohistochemical staining 
of cleaved caspase 3. Ten fields were selected 
randomly from each section of different groups 
(3-8 animals/group); LEICA QWIN software 
(Germany) was used. The graph shows the 
percentage of stained areas related to the total 
area investigated; about 200 cells were evaluated 
per observation field, stained cells were counted 
and expressed as percentage of total cells 
investigated.  
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3.14 Smad7 overexpression reduces proliferation of hepatocytes in CCl4 
treated mice 
Proliferating cell nuclear antigen (PCNA, 36 kDa), also known as cyclin, is an auxiliary protein of DNA polymerase that 
is essential for DNA replication during S phase of the cell cycle. The protein is present in the nucleoplasm of continually 
cycling cells throughout the cell cycle (Waseem, N., and Lane, D., 1990). PCNA begins to accumulate during G1 phase 
of the cell cycle, is most abundant during S phase, and declines during G2/M phase. The predominant distribution of 
PCNA also appears to change within the stages of the cell cycle.  
Monoclonal anti-proliferating cell nuclear antigen (PCNA) (mouse IgG2a isotype) antibodies were used to analyse cell 
proliferation and its relation with Smad7 overexpression. The results suggest a proportional correlation between the 
degree of tissue damage and cell proliferation (figure 3.44). As figure 3.44 indicates anti-PCNA signals appear 
predominantly in fibrotic areas after CCl4 treatment. Quantitative analysis of PCNA immunohistochemical staining 
shows only small differences of PCNA signals in cells of CCl4 treated animals. 15.1 ± 1.5 %, 17.5 ± 1.6% and 14 ± 
2.3% of immunostained areas in cell sections of FVB (n = 10), S7tg (n = 10) and CD-1 (n = 8) mice could be detected 
respectively. Tissue sections of S7∆E1 mice show the highest amount of anti-PCNA signals i.e. 34.9 ± 3.3% (figure 
3.45). LPS treatment alone did not induce any proliferation. Immunohistochemical staining with anti-PCNA antibodies 
revealed no difference of LPS treated cells to untreated cells of the control. After CCl4 + LPS treatment in contrast, S7tg 
cell sections exhibit 6.6 ± 1.3% of immunostained areas, whereas sections of FVB wild type mice show threefold more 
anti-PCNA signals i.e., 18.8 ± 2.1%. This reduction can be attributed to transgenic derived Smad7 overexpression in 
hepatocytes triggered by LPS administration (Table 3.12 and figure 3.44).  
 
Table 3.12: Quantification of immunohistochemical staining of PCNA in mouse liver sections as indicated. n=number of animals investigated, 
n. d.: not determined. Percentages give the relation between stained areas and the total area investigated. 
 
Experimental mice Control (%) CCl4 (%) LPS (%)  CCl4 + LPS (%) 
FVB (n = 10) 0.3 ± 0.4 15.1 ± 1.5 0.5 ± 0.5 18.6 ± 2.1 
S7tg (n = 10)  0.21 17.5  ± 1.6 0.3 ± 0.4 6.6 ± 1.3 
CD-1 (n = 8) 0.31 14  ± 2.3 n. d. n. d. 
S7?E1 (n = 8) 0.32 34.9 ± 3.3 n. d. n. d. 
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Figure 3.44: Smad7 overexpression leads to a 
blockade of TGF-β signaling and a decrease of 
hepatocyte proliferation after CCl4 induced 
liver damage. (A) Representative 
photomicrographs of mouse liver sections of 
S7tg and FVB mice treated for 8 weeks with 
CCl4 and LPS are shown. Untreated cells serve 
as a control. Immunohistochemical staining of 
PCNA was performed to analyse hepatocyte 
proliferation. Arrows indicate positive signals. 
Magnification x 200. (B) Morphometric 
quantification of anti-PCNA immunostaining. 
Ten fields were selected randomly from each 
section of different groups (8-10 
animals/group); LEICA QWIN software 
(Germany) was used. The graph shows the 
percentage of stained areas related to the total 
area investigated; about 200 cells were 
evaluated per observation field, stained cells 
were counted and expressed as a percentage of 
total cells investigated. 
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Figure 3.45: Loss of Smad7 leads to an intensification 
of TGF-β signaling and an increase of hepatocyte 
proliferation after CCl4 induced liver damage. (A) 
Representative photomicrographs of mice liver 
sections from S7∆E1 and CD-1 animals treated for 8 
weeks with both CCl4 and LPS are shown. Untreated 
cells serve as a control. Anti-PCNA 
immunohistochemical staining was performed to assay 
hepatocyte proliferation. Brown staining indicates 
positive signals; magnification x 200. (B) 
Morphometric quantification of immunohistochemical 
staining of PCNA. Ten fields were selected randomly 
from each section of different groups (3-8 
animals/group); LEICA QWIN software (Germany) 
was used. The graph shows the percentage of stained 
area related to the total area investigated; about 200 
cells were evaluated per observation field, stained 
cells were counted and expressed as a percentage of 
total cells investigated.  
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3.15 Smad7 overexpression in hepatocytes blunts inflammation in CCl4 
treated mice 
An important marker for determination of inflammation states is CD43, expressed on peripheral T cells (Baecher et al; 
1988 and Gulley et al 1988), on thymocytes (Jones et al 1994), and on early myeloid and lymphoid hematopoietic 
precursors within the bone marrow (Moore et al 1994). CD43 has been shown to be involved in a number of T cell-
mediated responses, including co-stimulation of proliferation (Rosenstein et al 1991), enhanced cytotoxicity of CD8 and 
T cells (Mosley et al 1994) and leukocyte adhesion (Axelsson et al 1988 and Nong et al 1989).  
In order to determine the effect of Smad7 overproduction in hepatocytes on inflammations, an accompanying symptom 
of fibrosis, immunohistochemical staining with anti-CD43 antibodies (BD Pharmingen) was performed (table 3.13 and 
figure 3.46 and 3.47). The analysis indicates that CCl4 treatment of mice causes strong CD43 expression. CD43 could be 
detected predominantly in damaged regions of liver tissues. Tissue sections of S7∆E1 mice (n = 8) exhibit most anti-
CD43 signals, i.e. 29 ± 0.92 %. (Table 3.13 and figure 3.47). Unexpectedly, FVB wild type (n = 10) shows little less 
CD43 signals than S7tg (n = 10), i.e. 13.8 ± 1.7 % and 17 ± 1.1 %, respectively. But in cells of CCl4 + LPS treated S7tg 
mice significantly less CD43 signals were detected (3 ± 0.92%). In contrast, the amount of CD43 signals in FVB wild 
type cells remained unchanged after LPS co-injection. It is threefold higher than in cells of S7tg mice (12.75 ± 1.4 %). 
S7∆E1 strain mice show most CD43 signals, i.e. (29 ± 0.92%). The corresponding CD-1 wild type cells show only 16.8 
± 1.2 % of CD43 staining. This result points out the enormous decrease of CD43 signals in S7tg mice in comparison to 
S7∆E1 mice exhibiting six fold as many CD43 signals. This peak can be correlated to highest extent of liver damage in 
this mouse strain.  
Further, this finding confirms that Smad7 overexpression in hepatocytes can inhibit CCl4 induced liver fibrosis and 
blunts the inflammatory state of the liver of those animals. 
 
Table 3.13: Quantification of immunohistochemical staining of CD43. n=number of animals investigated, n. d.: not determined. Percentages 
give the amount of stained area in relation to the total area investigated. For more information see legends of figures 3.46 and 3.47. 
 
Experimental mice Control (%) CCl4 (%) LPS (%)  CCl4 + LPS (%) 
FVB (n = 10) 0.12 13.8 ± 1.7 0.5 12.8 ± 1.4 
S7tg (n = 10)  0.13 17 ± 1.06 0.3 3 ± 0.9 
CD-1 (n = 8) 0.2 16.8 ± 1.2 n. d. n. d. 
S7?E1 (n = 8) 0.3 29 ± 0.9 n. d. n. d. 
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Figure 3.46: Smad7 overexpression leads to a 
blockade of TGF-β signaling and a decrease of 
inflammation after CCl4 induced liver damage. 
(A) Representative photomicrographs of mouse 
liver sections of S7tg and FVB mice treated for 
8 weeks with both CCl4 and LPS as indicated 
are shown. Untreated cells serve as a control. 
Immunohistochemical staining of CD43 was 
performed to indicate inflammation. Arrows 
indicate positive signals; magnification x 200. 
.(B) Morphometric quantification of 
immunohistochemical staining of CD43. Ten 
fields were selected randomly from each 
section of different groups (8-10 
animals/group); LEICA QWIN software 
(Germany) was used. The graph shows the 
percentage of stained areas related to the total 
area investigated. About 200 cells were 
evaluated per observation field, stained cells 
were counted and expressed as a percentage of 
total cells investigated.  
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Figure 3.47: Loss of Smad7 leads to an intensification of 
TGF-β signaling and an increase of hepatocyte 
inflammation after CCl4 induced liver damage. (A) 
Representative photomicrographs of mice liver sections of 
S7∆E1 and CD-1 mice treated for 8 weeks with both CCl4 
and LPS as indicated are shown. Untreated cells serve as a 
control. Immunohistochemical staining of PCNA was 
performed to analyse hepatocyte proliferation. Brown 
staining indicates positive signals; magnification x 200. (B) 
Morphometric quantification of immunostaining of CD43. 
Ten fields were selected randomly from each section of 
different groups (3-8 animals/group); LEICA QWIN 
software (Germany) was used. The graph shows the 
percentage of stained areas related to the total area 
investigated; about 200 cells were evaluated per observation 
field, stained cells were counted and expressed as 
percentage of total cells investigated. 
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4 Discussion 
TGF-β is known to play a central role in fibrogenesis. Therefore numerous antifibrotic strategies aim to block action of 
this cytokine or reduce its synthesis. One strategy is application of antisense mRNA, as reported by Arias et al., [4]. 
Thus, synthesis and autocrine signaling of TGF-β was suppressed in HSCs by an adenovirus expressing antisense 
mRNA (Ad5-CMV-asTGF-β1) targeting the 3´coding sequence of TGF-β1. In that study, Col1A1, α-SMA, LTBP-1, 
TβRI, and TβRII, which are increased during fibrogenesis, decreased after expression of antisense mRNA.  
As a model of irreversible fibrosis in rats Qi et al., [94] and Ueno et al., [120] used dimethylnitrosamine (DMN). Both 
groups successed in blocking the TGF-β signaling pathway using expression of either a dominant negative or a soluble 
type II TGF-β receptor (TβRII) . Rats infected with adenoviruses expressing these constructs survived the harmful effect 
of DMN, whereas control rats died of fibrosis. The authors concluded that anti-TGF-β treatment prevents fibrosis and 
preserves organ function, thus being therapeutically useful. Similarly, fibrosis induced by chronic bile duct ligation 
(BDL) was suppressed by ectopic expression of a fusion protein consisting of the Fc domain of immunoglobin G and the 
extracellular portion of TβRII [43].   
Since Smad7 represents an efficient inhibitor of TGF-β signaling, it is conceivable that hyperexpression of Smad7 is an 
additional means to antagonize TGF-β in fibrogenesis. Thus, bleomycin-induced lung fibrosis was reduced by 
intratracheal injection of a recombinant adenovirus containing Smad7 cDNA [82]. Furthermore, gene transfer of Smad7 
into obstructive kidney fibrosis prevented accumulation of ECM in this organ [113], confirming the above mentioned 
hypothesis. 
In a part of my own work, we studied the effect of Smad7 overexpression after adenoviral gene transfer (AdSmad7) in 
primary cultured HSCs and in vivo after BDL of rats [34]. Exogenous Smad7 overexpression prevented BDL dependent 
activation of HSCs and liver fibrosis. Collagen I deposition and hydroxyproline content were significantly reduced in 
Smad7 overexpressing livers. Although Smad7 overexpression did not reduce expression of α-SMA, a marker for HSC 
transdifferentiation, in cultured HSCs, it was strongly reduced in Smad7 overexpressing rats. We concluded that Smad7 
overexpression completely inhibits autocrine and paracrine TGF-β signaling in HSCs, leading to abrogation of Smad2/3 
activation and subsequent downstream events. Our results further indicate that HSCs remained in a quiescent stage after 
Smad7 overexpression confirming the important role of TGF-β signaling during the early phase of HSC activation.  
As AdSmad7 viruses infected and resided in all cell types of the liver, specificity of its effect could not be related to a 
single cell type. Even an influence on other organs could not be excluded.  
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In my thesis I therefore established an animal model with inducible overexpression of transgenic Smad7 in hepatocytes 
(S7tg mice) and studied its effect on fibrogenesis after CCl4 induced liver damage. In contrast to albumin/TGF-β1 
transgenic mice of Sanderson and colleagues [103], the mortality rate of S7tg mice was infinitely small during the CCl4 
treatment protocol I used. 
In S7tg mice the Smad7 gene was expressed under the control of the human CRP promoter. CRP is a component of the 
congenital immune system stimulated by LPS. Binding of LPS to cell surface receptors triggers the synthesis of 
inflammatory cytokines including IL-6, which then induces expression of CRP [1]. Because CRP and its transcription 
factors are mainly expressed in hepatocytes, this new mouse model leads to specific Smad7 expression in hepatocytes.  
Liver histology analysis pointed to similar morphology of liver tissues in untreated S7tg mice and corresponding FVB 
wild type mice. LPS, used to induce the CRP promoter, is known to trigger expression of cytokines like TNF-α, thereby 
strengthening the profibrotic effect of TGF-β1[101] and  [48]. Further, it was previously reported that LPS treatment 
may result in activation of Kupffer cells to release various kinds of cytokines and inflammatory mediators, thus inducing 
liver injury [88], [45], [31] and [125]. Even exposure to smaller LPS doses can result in a modest, noninjurious 
inflammatory response [42]; [76] and [74]. On the other hand it was recently shown that LPS treated animals can 
develop endotoxin tolerance taking advantage of the scavenger character of kupffers cells and liver sinusoidal 
endothelial cells clearing circulating blood from LPS [121]. Moreover, production and signaling of IL-10 have been 
proven to be important for protection against liver injury in mice [33] and [53]. In summary, the initial burst of 
proinflammatory gene expression in response to LPS is proposed to be short-lived and replaced by the prolonged 
expression of various anti-inflammatory genes. This can lead to an immunosuppressed state which is characterized by 
LPS tolerance [23], [37] and [129]. In order to reduce stress, liver damage and mortality due to LPS treatment, but 
nevertheless avoid simultaneous development of LPS tolerance, I started to treat the animals with a relatively small 
dosage of LPS (10 µg/injection; being sufficient to stimulate CRP-Smad7 construct), and increased it after 6 weeks to 25 
µg/injection. In comparison, other authors worked with dosages up to 100 mg/kg, i.p. [140]. Despite very low doses of 
LPS, I could show expression of Smad7 in S7tg mice both, directly and indirectly by detecting the Flag-tag. This 
indicates LPS dependent activation of the ectopic CRP promoter and subsequent transgene expression specifically in 
hepatocytes.  
Although LPS alone had no influence on the state of liver fibrosis in my study, the agent multiplied the harmful, fibrotic 
effect of CCl4. When both agents were injected simultaneously into FVB mice this could even lead to death. To limit 
mortality, experimental mice determined for CCl4 and LPS treatment have been injected at alternate days with both 
agents.  
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Comparing the extent of liver damage between wild type, S7tg and S7∆E1 mice caused by CCl4 a significant increase of 
fibrosis in S7∆E1 mice was detected, whereas in S7tg mice fibrotic effects were attenuated after LPS induced Smad7 
expression. This includes the reduction of collagen I, α-SMA, serum enzymes, hyaluronic acid and hydroxyproline in 
S7tg mice. Further, immunostaining of liver tissues and Western blot analysis of Phospho-Smad2 and Phospho-Smad3 
show a strongly reduced nuclear localization of both proteins. These results can be interpreted to be due to antifibrotic 
effects of Smad7 overexpression interrupting the TGF-β signaling pathway in hepatocytes.  
Although the reduction of serum enzymes might be due to a role of hepatocyte residing TGF-β/Smad7 in liver damage 
or regeneration, this finding is in contrast to our previous study with adenoviral Smad7 expression. A similar 
contradicting tendency was reported by Qi et al., Nakamura et al. and Yata et al. who used dominant negative TβRII 
adenovirus constructs or a soluble TβRII variant as antifibrotic approaches [94], [80] and [139]. The difference of my 
results to those studies might depend on different methods of fibrosis induction (BDL versus CCl4), cell type specific 
effects (hepatocyte specific Smad7 versus general delivery of an adenoviral Smad7 construct), or different points of 
interference with the signaling pathway (ligand itself versus type I receptor/R-Smad activation).  
To complete my study after comparing expression of ECM and serum proteins I investigated the influence of Smad7 
overexpression in hepatocytes on TGF-β dependent processes like apoptosis, inflammation and cell proliferation. TGF-β 
is described as one of the most potent inducers of apoptosis in normal hepatocytes [75], [103], Arsura [5]. Hepatocytes 
protect themselves against the pro-apoptotic effect of TGF-β by morphological transdifferentiation, a process termed 
epithelial mesenchymal transition (EMT). EMT includes loss of cell cell and cell matrix interactions through 
downregulation of E-cadherin and β-catenin [104] and  [14]), migration, basement membrane degradation through 
matrix metalloproteinase-2 (MMP-2) [137] and cytoskeletal rearrangements including expression of α-SMA [118] and 
activation of Snail. All these events are normal parts of tissue repair, however, if occurring unregulated, they may 
contribute to chronic fibrosis and apoptosis. 
In line with this, disrupting the TGF-β signaling pathway in hepatocytes of S7tg mice resulted in reduced apoptosis. A 
proportional relationship between increased TGF-β signaling and apoptosis was demonstrated by anti-caspase-3 signals 
appearing mainly in fibrotic areas of liver cells. Blocking TGF-β signaling in hepatocytes by Smad7 overexpression 
reduced apoptosis in S7tg mice significantly compared to FVB wild type mice and even more drastically in comparison 
to S7∆E1 mice.  
Determination of hepatocyte proliferation was carried out by immunohistochemical staining of PCNA, a marker for cell 
proliferation. PCNA staining increased in parallel with the extent of liver damage and was restricted to fibrotic regions. 
These data contradict the postulated inhibitory effect of TGF-β on cell proliferation; however, they are in line with 
findings of Date et al. [27], who examined this apparent paradox in more detail. They documented that hepatocytes may 
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proliferate despite the presence of a powerful antiproliferative stimulus. Date et al. further observed that isolated 
hepatocytes of CCl4 treated animals have reduced sensitivity to antiproliferative effects of TGF-β1, compared to 
hepatocytes from normal rats. Concurrently, a dose dependent induction of fibronectin expression and proliferation 
inhibition by TGF-β1 in HSCs was observed, which was not differentially regulated by CCl4 treatment. To explain the 
different sensitivity of HSCs and hepatocytes to TGF-β after CCl4 induced injury, binding of radiolabelled TGF-β1 to 
TGF-β type I receptors in HSCs and hepatocytes from normal and CCl4 treated livers was examined. They found that in 
hepatocytes in contrast to HSCs, TGF-β type I and II receptors were downregulated, thus providing an explanation for 
the observed reduction of TGF-β mediated growth inhibition of hepatocytes.  
Finally, the rate of inflammation, usually accompanying liver fibrosis, in dependency of hepatocyte specific Smad7 
expression was examined. Immunohistochemical staining with anti-CD43 antibodies points to a dramatic reduction of 
inflammation in livers of S7tg mice induced with LPS, in parallel with a decrease of detectable fibrosis. As expected the 
highest level of inflammation was measured in S7∆E1 mice, indicating a regulatory role of the negative feedback 
regulation of TGF-β signaling via Smad7 during intrinsic wound healing responses. Similarly, overexpression of Smad7 
in kidney inhibits renal inflammation in remnant kidney disease [52] and [84]. A direct anti inflammatory role for 
Smad7 within hepatocytes might be induction of IκBα, thus inhibiting NF-κB activation and a subsequent NF-κB–
driven inflammatory response 
Taken together, my thesis demonstrates that TGF-β signaling in hepatocytes is required for progression of chronic liver 
disease and blocking its signaling pathway in this cell type by ectopic expression of Smad7 is sufficient to obtain a 
beneficial outcome.  
 
Chapter 5 Summary 117 
 
5 Summary 
Chronic injury of the liver occurs in response to a variety of damages, including viral hepatitis, alcohol abuse, drugs and 
metabolic diseases. Liver fibrosis is reversible, whereas cirrhosis, the end-stage consequence, is generally not. Thus, 
efforts to understand fibrogenesis mechanisms should be focused on initiating events that lead to early accumulation of 
scar tissue in hope of identifying therapeutic targets to slow down this progression. 
Hepatic stellate cells (HSC) are important effectors in the diseased liver. In response to profibrogenic cytokines such as 
TGF-β1, HSCs undergo an activation process that involves proliferation, exhibition of a myofibroblastic phenotype and 
enhanced production of ECM proteins. Strategies aiming at blocking TGF-β1 synthesis and/or its signaling pathways 
significantly decrease fibrosis in experimental models. 
In a further approach targeting TGF-β signaling in fibrogenesis, we used TGF-β antagonistic Smad7 and were able to 
blunt disease progression after adenoviral delivery. To monitor the effect of a cell type specific abrogation of TGF-β 
signaling in chronic liver disease, transgenic mice were generated, which express mouse Smad7 under the control of the 
human C-reactive protein (CRP) promoter. In this model, transgenic Smad7 overexpression was induced by 
lipopolysaccharide injections specifically in hepatocytes. These mice and corresponding controls were treated with CCl4 
for 8 weeks. In addition, mice with a disrupted Smad7 gene (S7∆E1) were investigated. The S7∆E1 strain displayed the 
highest degree of fibrosis, indicating that the presence of a functional negative feedback regulation for TGF-β signaling 
is controling the degree of fibrogenesis. Interestingly, Smad7 overexpression in hepatocytes of CRP-Smad7 transgenic 
mice was sufficient to reduce fibrosis and expression of protein markers in the liver, e.g., collagen and α-SMA, as well 
as in serum, e.g., AST, ALT, AP and HA, by more than 70% in comparison to wild type animals. Further, Smad7 
overexpression reduces proliferation, inflammation and apoptotic processes in liver cells of CRP-Smad7 transgenic 
mice.  
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